<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098542</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1573037</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Nanotechnology-driven advances in intranasal vaccine delivery systems against infectious diseases</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Zhihan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3033381/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yang</surname><given-names>Yumeng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3045896/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Huang</surname><given-names>Liwen</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3045463/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yuan</surname><given-names>Lei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3045857/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Sijian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3044898/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Zihang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3045348/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Yuan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3044876/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Xianghong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3044991/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Xiaomei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2775154/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Shi</surname><given-names>Mingsong</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/696809/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhong</surname><given-names>Maohua</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#x02021;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2970016/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College, Wuhan University of Science and Technology</institution>, <addr-line>Wuhan, Hubei</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Analytical &#x00026; Testing Center, Wuhan University of Science and Technology</institution>, <addr-line>Wuhan, Hubei</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China</institution>, <addr-line>Mianyang, Sichuan</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Srinivasa Reddy Bonam, Indian Institute of Chemical Technology (CSIR), India</p></fn><fn fn-type="edited-by"><p>Reviewed by: Himanshu Gogoi, Translational Health Science and Technology Institute (THSTI), India</p><p>Patr&#x000ed;cia C. C. Neves, Oswaldo Cruz Foundation, Brazil</p><p>Rahmi Anggraeni, National Research and Innovation Agency (BRIN), Indonesia</p></fn><corresp id="fn001">*Correspondence: Maohua Zhong, <email xlink:href="mailto:zmh@wust.edu.cn">zmh@wust.edu.cn</email>; Xiaomei Wang, <email xlink:href="mailto:wangxiaomei@wust.edu.cn">wangxiaomei@wust.edu.cn</email>; Mingsong Shi, <email xlink:href="mailto:shims90@sc-mch.cn">shims90@sc-mch.cn</email>
</corresp><fn fn-type="equal" id="fn003"><p>&#x02020;These authors have contributed equally to this work</p></fn><fn fn-type="equal" id="fn004"><p>&#x02021;Lead Contact</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1573037</elocation-id><history><date date-type="received"><day>10</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Zhang, Yang, Huang, Yuan, Huang, Zeng, Cao, Wei, Wang, Shi and Zhong</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Zhang, Yang, Huang, Yuan, Huang, Zeng, Cao, Wei, Wang, Shi and Zhong</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Outbreaks of emerging and re-emerging infectious diseases have consistently threatened human health. Since vaccinations are a powerful tool for preventing infectious illnesses, developing new vaccines is essential. Compared to traditional injectable vaccines, mucosal vaccines have the potential to offer more effective immune protection at mucosal sites. Mucosal immunization strategies include sublingual, oral, intranasal, genital, and rectal routes, in which intranasal immunization being the most efficient and applicable method for mucosal vaccine delivery. Nevertheless, low antigen availability and weak immunogenicity making it challenging to elicit a potent immune response when administered intranasally, necessitating the incorporation of immune delivery systems. However, there is a notable absence of reviews that summarize the intranasal vaccine delivery system against infectious disease. Therefore, this review summarizes the recent advances in intranasal delivery systems, classified by physical and chemical properties, and proposes potential improvement strategies for clinical translation. This review elucidates the potential and current status of intranasal delivery systems, while also serving as a reference point for the future development of intranasal vaccines.</p></abstract><kwd-group><kwd>infectious disease</kwd><kwd>vaccine</kwd><kwd>mucosal vaccination</kwd><kwd>intranasal immunization</kwd><kwd>delivery system</kwd></kwd-group><funding-group><funding-statement>The author(s) declare financial support was received for the research, and/or publication of this article. This work was supported by NHC Key Laboratory of Nuclear Technology Medical Transformation (MIANYANG CENTRAL HOSPITAL, Nos. 2024HYX027 and 2024HYX001), Undergraduate Innovation and Entrepreneurship Training Program in Hubei Province (No. S202410488174), Hubei Province Key Laboratory of Occupational Hazard Identification and Control (No. OHIC2024G02), the National Natural Science Foundation of China (Nos. 81971568 and 81302600), the Scientific research plan of Education Department of Hubei Province (No. B2023016), &#x0201c;The 14th Five Year Plan&#x0201d; Hubei Provincial advantaged characteristics disciplines (groups) project of Wuhan University of Science and Technology (No. 2023C0307) and Innovation research Fund of Wuchang Hospital (No. WCYY2022G01).</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="5"/><equation-count count="0"/><ref-count count="132"/><page-count count="18"/><word-count count="8505"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Vaccines and Molecular Therapeutics</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Infectious diseases including influenza, acquired immune deficiency syndrome (AIDS), measles, and coronavirus disease 2019 (COVID-19) pose persistent threats to global public health, necessitating urgent advancements in prophylactic strategies (<xref rid="B1" ref-type="bibr">1</xref>). While medical advancements over the past two decades have reduced mortality through improved sanitation and healthcare infrastructure (<xref rid="B2" ref-type="bibr">2</xref>), the emergence of novel pathogens and antimicrobial resistance underscores the need for innovative immunization approaches. As the cornerstone of infectious disease prevention, vaccines function by priming innate immunity to activate antigen-specific adaptive responses through antibody production and T-cell mediation&#x02014;a dual mechanism that curbs pathogen transmission while protecting vulnerable populations (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>Current vaccine delivery modalities can be broadly categorized into systemic injection and mucosal immunization. In contrast to traditional injectable vaccines that primarily elicit systemic immunity, mucosal vaccines offer dual protective advantages: 1) induction of both systemic and mucosal immune responses, 2) generation of secretory IgA and tissue-resident memory T cells at portal-of-entry mucosal sites, and 3) needle-free administration that enhances safety and compliance (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Given that &#x0003e;90% of pathogens invade through mucosal surfaces, mucosal immunization serves as the primary immunological barrier against infection establishment (<xref rid="B6" ref-type="bibr">6</xref>).</p><p>Among mucosal delivery routes&#x02014;including oral, buccal, sublingual, intranasal, and genital approaches&#x02014;intranasal immunization stands out as a particularly promising candidate. This preference stems from the nasal cavity&#x02019;s unique immunological architecture: 1) dense networks of microfold (M) cells and antigen-presenting cells (APCs) within nasal-associated lymphoid tissue (NALT), 2) vascularized subepithelial layers facilitating rapid systemic absorption, and 3) interconnected mucosal immunity enabling cross-protection at distal sites such as pulmonary and intestinal mucosa (<xref rid="B7" ref-type="bibr">7</xref>). Notably, currently approved intranasal vaccines predominantly target influenza, including FluMist (US) (<xref rid="B8" ref-type="bibr">8</xref>) and Nasovac-S (India) (<xref rid="B9" ref-type="bibr">9</xref>). The COVID-19 pandemic further accelerated clinical development of intranasal SARS-CoV-2 vaccines (<xref rid="B10" ref-type="bibr">10</xref>), with emergency approvals granted for formulations acting as primary immunogens or heterologous boosters to enhance mucosal immunity and tissue-resident memory T cells (<xref rid="B11" ref-type="bibr">11</xref>) (<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>).</p><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Currently approved intranasal vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Disease</th><th valign="top" align="left" rowspan="1" colspan="1">Vaccine</th><th valign="top" align="left" rowspan="1" colspan="1">Type</th><th valign="top" align="left" rowspan="1" colspan="1">Country</th><th valign="top" align="left" rowspan="1" colspan="1">Links</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="3" colspan="1">influenza</td><td valign="top" align="left" rowspan="1" colspan="1">FluMist</td><td valign="top" align="left" rowspan="1" colspan="1">Live attenuated vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">MedImmune, LLC</td><td valign="top" align="left" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.fda.gov/media/180697/download?attachment" ext-link-type="uri">https://www.fda.gov/media/180697/download?attachment</ext-link>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FluMist Quadrivalent</td><td valign="top" align="left" rowspan="1" colspan="1">Live attenuated vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">MedImmune, LLC</td><td valign="top" align="left" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.fda.gov/media/160349/download?attachment" ext-link-type="uri">https://www.fda.gov/media/160349/download?attachment</ext-link>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nasovac-S4</td><td valign="top" align="left" rowspan="1" colspan="1">Live attenuated vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Serum Institute of India</td><td valign="top" align="left" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.seruminstitute.com/product_ind_NASOVAC-S4.php" ext-link-type="uri">https://www.seruminstitute.com/product_ind_NASOVAC-S4.php</ext-link>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COVID-19</td><td valign="top" align="left" rowspan="1" colspan="1">BBV154</td><td valign="top" align="left" rowspan="1" colspan="1">adenovirus vector vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Bharat Biotech</td><td valign="top" align="left" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.bharatbiotech.com/intranasal-vaccine.html" ext-link-type="uri">https://www.bharatbiotech.com/intranasal-vaccine.html</ext-link>
</td></tr></tbody></table><table-wrap-foot><fn><p>The data is derived from FDA, Serum Institute of India, Bharat Biotech provided in the websites.</p></fn></table-wrap-foot></table-wrap><p>The clinical advantages of intranasal vaccines are multifaceted: (i) Non-invasive administration: Intranasal vaccines are an excellent non-invasive vaccination method (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B12" ref-type="bibr">12</xref>). (ii) Induction of mucosal immunity: In addition to systemic immune response, intranasal vaccines can act on the extensive respiratory mucosa, eliciting mucosal immunity and providing more comprehensive and effective protection for the human body (<xref rid="B12" ref-type="bibr">12</xref>). (iii) Improved pediatric compliance: compared to the pain caused by intramuscular injections, nasal drops offer a more comfortable vaccination experience for children and are also suitable for other individuals with needle or pain phobias (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). (iv) Operational and economic benefits: intranasal vaccines offer greater practicality in terms of cost and ease of administration (<xref rid="B15" ref-type="bibr">15</xref>). While transient adverse effects (e.g., rhinorrhea, low-grade fever) occur in some recipients, these typically resolve without intervention (<xref rid="B16" ref-type="bibr">16</xref>).</p><p>The nasal cavity is a complex anatomical structure with superior, inferior, medial, and lateral walls. The two nasal passages have a combined surface area of about 160 cm<sup>2</sup> (96 m<sup>2</sup> if nasal epithelial microvilli are included), and a combined volume of about 15 mL. The nasal cavity can be divided into three main regions: the nasal vestibule, the respiratory tract, and the olfactory region. The nasal septum, which separates the two nasal passages, forms the medial wall of the nasal cavity. The superior, middle, and inferior turbinates, which delineate the upper, middle, and lower nasal passages respectively, constitute the lateral wall of the nasal cavity (<xref rid="B17" ref-type="bibr">17</xref>). The human Waldeyer&#x02019;s ring, comprising the adenoid, lingual tonsil, two palatine tonsils, and two tubal tonsils, is believed to be analogous to the NALT (nasal-associated lymphoid tissue) observed in rodents (<xref rid="B8" ref-type="bibr">8</xref>). The NALT can be defined as an organized mucosal-associated lymphoid tissues within the nasal mucosa, consisting of lymphoid tissue, B cells, T cells, antigen-presenting cells (APCs) and microfold (M) cells. M cells are specifically for antigen uptake (<xref rid="B9" ref-type="bibr">9</xref>). NALT plays a critical role in antigen recognition and immune activation following intranasal immunization, serving as a key site for immune induction within the nasal mucosa (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>).</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Anatomy of and immune induction in nasal-associated lymphoid tissues in rodents. <bold>(A-C)</bold> Anatomical location of NALT: The sagittal anatomy of mouse nasal tissues can be divided into two distinct regions&#x02014;the respiratory and olfactory parts&#x02014;based on the structure and function of the mucosa <bold>(A)</bold>. A specialized structure in the nasal tissue, the nasal mucosa-associated lymphoid tissue (NALT), consists of two parallel bell-shaped formations located above the hard palate <bold>(B, C)</bold>. Immune response in NALT: The immune response in NALT progresses through three main stages: antigen uptake and presentation, immune cell activation, and the subsequent immune response. Antigens entering the nasal cavity are first internalized by microfold cells (M cells), which then transport them into NALT, where dendritic cells further process and present the antigens. In addition, some dendritic cells are capable of crossing the epithelial barrier by extending their dendrites, allowing them to directly capture antigens. Antigen-loaded dendritic cells activate both CD4<sup>+</sup> and CD8<sup>+</sup> T cells upon antigen presentation. Activated CD4<sup>+</sup> T cells further stimulate B cells via CD40L/CD40 interaction, promoting their differentiation into plasma cells. These fully differentiated plasma cells subsequently initiate an immune response at the effector site through the production of IgA and IgG antibodies <bold>(D)</bold>. NT, nasoturbinate; MT, maxillary turbinate; ET, ethmoid turbinate; S, septum; HP, hard palate.</p></caption><graphic xlink:href="fimmu-16-1573037-g001" position="float"/></fig><p>Low antigen availability and weak immunogenicity, combined with antigen clearance by nasal cilia, the mucous layer barrier, and tight junctions between epithelial cells, significantly reduce vaccine uptake. This hinders the elicitation of a robust immune response, thereby posing challenges for nasal administration (<xref rid="B18" ref-type="bibr">18</xref>). The nasal drug delivery system (NDDS) is a needle-free, non-invasive, and efficient method for delivering drugs, vaccines, and other therapeutic agents into the human body via the nasal route which include nanoparticles (<xref rid="T2" ref-type="table">
<bold>Tables&#x000a0;2</bold>
</xref>, <xref rid="T3" ref-type="table">
<bold>3</bold>
</xref>), nanoemulsions, and some microbial preparations (<xref rid="T4" ref-type="table">
<bold>Table&#x000a0;4</bold>
</xref>) (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B19" ref-type="bibr">19</xref>). Among them, nanoparticles are the most widely used, which include polysaccharide-based particles, poly lactide-co-glycolide (PLGA), gold nanoparticles, nanogels, lipopeptides, liposomes and others (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). Through boosting antigen penetration, shielding the antigen from degradation, facilitating sustained antigen release, improving nasal retention time, and recruiting/activating APCs, the nasal delivery system can significantly increase the antigen availability and immunogenicity (<xref rid="B18" ref-type="bibr">18</xref>). The NDDS offers the advantage of boosting vaccination efficiency against pathogens through the induction of both systemic and mucosal immune responses at respiratory and distal mucosal sites (<xref rid="B21" ref-type="bibr">21</xref>).</p><table-wrap position="float" id="T2"><label>Table&#x000a0;2</label><caption><p>Preclinical studies of intranasal vaccines using polysaccharides as an intranasal delivery system.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Type of particle</th><th valign="top" align="left" rowspan="1" colspan="1">Species</th><th valign="top" align="left" rowspan="1" colspan="1">Antigen</th><th valign="top" align="left" rowspan="1" colspan="1">Immunization parameters</th><th valign="top" align="left" rowspan="1" colspan="1">Key outcome</th><th valign="top" align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="4" colspan="1">chitosan</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 S-RBD</td><td valign="top" align="left" rowspan="1" colspan="1">CS &#x00026; O-HTCC/5&#x003bc;g of S-RBD/immunotherapy in three doses with 14-day intervals</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02191;of the humoral, mucosal and cellular immune responses.<break/>CS/S-RBD/O-HTCC with two antigens could induced neutralizing antibodies against both the ancestral and mutated S-RBD</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B25" ref-type="bibr">25</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">recombinant H1N1 hemagglutinin protein</td><td valign="top" align="left" rowspan="1" colspan="1">C-O-NP/20 &#x003bc;L(containing 1.5&#x003bc;g HA)/immunotherapy in 2 doses on days 0 and 14</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02191;of the cellular immune responses<break/>Stimulated proximal and distal mucosal immune responses through antigen-specific sIgA in both saliva and vaginal lavage fluid</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B30" ref-type="bibr">30</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6 mice</td><td valign="top" align="left" rowspan="1" colspan="1">HBsAg</td><td valign="top" align="left" rowspan="1" colspan="1">Chi-C48/80 NPs/15&#x003bc;L of vaccine formulation (7.5&#x000b5;L per nostril)/immunotherapy in 3 doses on Days 0, 7, and 21</td><td valign="top" align="left" rowspan="1" colspan="1">Induced humoral and mucosal antibodies against HBV (anti-HBsAg IgA, specific IgG)</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B32" ref-type="bibr">32</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">HBsAg</td><td valign="top" align="left" rowspan="1" colspan="1">GC NPs/immunotherapy in 2 doses on Days 0 and 21</td><td valign="top" align="left" rowspan="1" colspan="1">Elicited stronger humoral and mucosal immune response and lower rate of clearance from the nasal cavity compared to chitosan NPs after nasal administration</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B31" ref-type="bibr">31</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Starch</td><td valign="top" align="left" rowspan="1" colspan="1">Balb/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">Human serum<break/>albumin (HSA)</td><td valign="top" align="left" rowspan="1" colspan="1">HSA containing TS-PDMS-grafted MP/10 ul per dose/intranasally vaccinated on days 0, 7 and 14</td><td valign="top" align="left" rowspan="1" colspan="1">Elevated anti-HSA serum IgG levels</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B36" ref-type="bibr">36</xref>)</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Pullulan</td><td valign="top" align="left" rowspan="1" colspan="1">Balb/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">pneumococcal surface protein A (PspA)</td><td valign="top" align="left" rowspan="1" colspan="1">cationic cholesteryl group-bearing pullulan nanogel with PspA/Once weekly for 3 consecutive weeks</td><td valign="top" align="left" rowspan="1" colspan="1">Elevated anti-PspA serum IgG and mucosal PspA-specific sIgA levels and enhanced bacterial clearance from BALF and the lung</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B42" ref-type="bibr">42</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">cynomolgus macaques</td><td valign="top" align="left" rowspan="1" colspan="1">PspA</td><td valign="top" align="left" rowspan="1" colspan="1">cationic cholesteryl group-bearing pullulan nanogel with PspA/25 ug per dose/nasally immunized five times at 2-week intervals</td><td valign="top" align="left" rowspan="1" colspan="1">PspA-specific bronchoalveolar lavage fluid IgG and nasal wash IgA responses exhibited higher levels</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B41" ref-type="bibr">41</xref>)</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Maltodextrin</td><td valign="top" align="left" rowspan="1" colspan="1">CBA/J (H-2k) mice</td><td valign="top" align="left" rowspan="1" colspan="1">Toxoplasma gondii antigen<break/>extract (TE)</td><td valign="top" align="left" rowspan="1" colspan="1">Maltodextrin (MD)-loaded TE/three doses intra-nasally at 2-week intervals of DGNP, free TE, CT, CT/TE and DGNP/TE (6&#x003bc;L/nostril)</td><td valign="top" align="left" rowspan="1" colspan="1">Higher levels of total IgG, the mixed IgG1/IgG2a response and a mixed Th1/Th17 response<break/>Protective immune response: higher reduction rate of TE cysts, reducing parasite growth and protecting mice against long-term infection</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B50" ref-type="bibr">50</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BALB/c and DBA/2J mice</td><td valign="top" align="left" rowspan="1" colspan="1">split Udorn virus antigens</td><td valign="top" align="left" rowspan="1" colspan="1">Maltodextrin (MD)-loaded split Udorn virus<break/>antigens/three times, 10 days apart of split Udorn only, split Udorn/NPL, split Udorn/CTA1-DD/NPL(5&#x003bc;l/nostril)</td><td valign="top" align="left" rowspan="1" colspan="1">Increased intracellular antigen delivery and specific humoral immune response<break/>Decreased viral titers<break/>Inhibited viral transmission</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B51" ref-type="bibr">51</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Alginate</td><td valign="top" align="left" rowspan="1" colspan="1">pigs</td><td valign="top" align="left" rowspan="1" colspan="1">Bee venom</td><td valign="top" align="left" rowspan="1" colspan="1">chitosan/alginate nanoparticles double encapsulated 1mg/2mg of BV and administered it one week before PRRSV challenge and 2 weeks after the challenge</td><td valign="top" align="left" rowspan="1" colspan="1">Showed significant increases in the populations of Th cells and PRRSV-specific IgG Ab levels. Viral loads in serum and tissues with PRRSV challenge decreased.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B54" ref-type="bibr">54</xref>)</td></tr></tbody></table><table-wrap-foot><fn><p>SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; S-RBD, spike receptor binding domain; CS, curdlan sulfate; O-HTCC, O-(2-hydroxyl) propyl-3-trimethyl ammonium chitosan chloride; C-O-NP, curdlan-chitosan conjugate nanoparticle; HA, hyaluronic acid; HBsAg, hepatitis B surface antigen; Chi-C48/80, compound 48/80 loaded chitosan; HBV, hepatitis B virus; IgA, immunoglobulin A; IgG, immunoglobulin G; GC, glycol chitosan; HAS, human serum albumin; TS-PDMS-grafted MP, 3-(triethoxysilyl)-propyl-terminated polydimethylsiloxane-grafted microparticles; PspA, pneumococcal surface protein A; BALF, bronchoalveolar lavage fluid; TE, total extract of Toxoplasma gondii antigens; MD, Maltodextrin; DGNP, Dendritic Gold Nanoparticles; CT, cholera toxin; CTA1-DD, cholera toxin A1 subunit -dimer of the D-fragment of protein A from Staphylococcus aureus bacteria; NPL, nanoparticles lipid; BCV, Bee venom; PRRSV, porcine reproductive and respiratory syndrome virus.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table&#x000a0;3</label><caption><p>Preclinical studies of other nanoparticles used in intranasal delivery system.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Type of particle</th><th valign="top" align="left" rowspan="1" colspan="1">Species</th><th valign="top" align="left" rowspan="1" colspan="1">Antigen</th><th valign="top" align="left" rowspan="1" colspan="1">Immunization parameters</th><th valign="top" align="left" rowspan="1" colspan="1">Key outcome</th><th valign="top" align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">PLGA</td><td valign="top" align="left" rowspan="1" colspan="1">mouse (J774) and human (THP-1) macrophage cell lines</td><td valign="top" align="left" rowspan="1" colspan="1">The antigenic peptide epitope of the ESAT-6 protein of M. tuberculosis</td><td valign="top" align="left" rowspan="1" colspan="1">PVP coated PLGA nanoparticle</td><td valign="top" align="left" rowspan="1" colspan="1">Augmented the macrophages with much less quantity of the antigenic peptide</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B63" ref-type="bibr">63</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AuNPs</td><td valign="top" align="left" rowspan="1" colspan="1">transgenic C57BL/6J-DR and BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2-spike DNA vaccine transported on a modified gold-chitosan nanocarrier/20 micrograms of DNA</td><td valign="top" align="left" rowspan="1" colspan="1">AuNP-chitosan- SARS-CoV-2-spike DNA vaccines effectively induced S-antigen specific IgG, IgA, and IgM responses in immunocompetent mice</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B69" ref-type="bibr">69</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6 mice</td><td valign="top" align="left" rowspan="1" colspan="1">Bm</td><td valign="top" align="left" rowspan="1" colspan="1">nano-glycoconjugate vaccine/10 &#x003bc;g of protein and 10 &#x003bc;g of LPS coupled to AuNPs and 20 &#x003bc;g of CpG</td><td valign="top" align="left" rowspan="1" colspan="1">Enhanced specific IgG titer and protection-related Th1-biased immune responses</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B70" ref-type="bibr">70</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nano gel</td><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6 mice</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">a gel system composed of a derivative of glutamine amide and benzaldehyde/given EVs hydrogel/solution intranasally, 2 &#x003bc;L each time</td><td valign="top" align="left" rowspan="1" colspan="1">Reduced the levels of pro-inflammatory Ly6C (high) monocytes/macrophages and neutrophils</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B76" ref-type="bibr">76</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lipopeptides</td><td valign="top" align="left" rowspan="1" colspan="1">Swiss outbred mice</td><td valign="top" align="left" rowspan="1" colspan="1">GAS epitope peptide</td><td valign="top" align="left" rowspan="1" colspan="1">Lipopeptides-loaded GAS epitope peptide (LP-88/30-J14, LP-88/30, LP-J14)/first immunization and followed by similar booster doses on days 21 and 41 post primary immunization&#x02003;</td><td valign="top" align="left" rowspan="1" colspan="1">Smaller lipopeptides were taken up more readily by APCs<break/>Significantly higher serum IgG antibody responses<break/>More efficient APC uptake, promoting the maturation of APCs</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B79" ref-type="bibr">79</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Liposomes</td><td valign="top" align="left" rowspan="1" colspan="1">mice</td><td valign="top" align="left" rowspan="1" colspan="1">H3N2, H1N1</td><td valign="top" align="left" rowspan="1" colspan="1">A self-assembling influenza virus vaccine platform that seamlessly converts soluble antigens into nanoparticles</td><td valign="top" align="left" rowspan="1" colspan="1">Induction of mucosal antibody responses and production of large amounts of IgA and IgG in respiratory tissues</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B86" ref-type="bibr">86</xref>)</td></tr></tbody></table><table-wrap-foot><fn><p>PLGA, poly(lactide-co-glycolide); ESAT, Early Secretory Antigenic Target; PVP, poly (4-vinylpyridine); AuNPs, Gold nanoparticles; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; IgA, immunoglobulin A; IgM, immunoglobulin M; IgG, immunoglobulin G; Bm, Burkholderia mallei; LPS, lipopolysaccharide; Th1, type-1 helper T cell; GAS, Group A Streptococcus; LP, Lipopeptides; APCs, antigen presenting cells.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table&#x000a0;4</label><caption><p>Preclinical studies for intranasal vaccination with other delivery systems.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Type of particle</th><th valign="top" align="left" rowspan="1" colspan="1">Species</th><th valign="top" align="left" rowspan="1" colspan="1">Antigen</th><th valign="top" align="left" rowspan="1" colspan="1">Immunization parameters</th><th valign="top" align="left" rowspan="1" colspan="1">Key outcome</th><th valign="top" align="left" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="2" colspan="1">nanoemulsion</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">Helicobacter pylori HpaA epitope peptide (P22)</td><td valign="top" align="left" rowspan="1" colspan="1">NE-loaded HpaA epitope peptide P22/four times at 1-week of the NE, NE-P22, NE-P22 with CpG, P22 with CpG 1826, P22 only, NE with CpG or CpG only(10&#x003bc;L/nostril)&#x02003;</td><td valign="top" align="left" rowspan="1" colspan="1">Enhancing the protective efficiency of the epitope vaccine against helicobacter pylori<break/>Promoting the maturation of BMDC<break/>Slowing the release of P22 <italic>in vitro</italic>, significantly prolonging nasal residence time <italic>in vivo</italic>
<break/>Effectively enhancing P22 uptake by CD11<sup>+</sup> DCs in nasal mucosal tissues</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B104" ref-type="bibr">104</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6 mice</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant SARS-CoV-2<break/>spike protein S1 subunit</td><td valign="top" align="left" rowspan="1" colspan="1">NE/IVT DI-loaded SARS-CoV-2 spike protein/three times at 4-week intervals of S1 only NE/S1, NE/IVT DI/S1(6&#x003bc;L/nostril)&#x02003;</td><td valign="top" align="left" rowspan="1" colspan="1">Higher serum antigen-specific IgG, IgA titers<break/>Higher virus-neutralizing antibody titers</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B105" ref-type="bibr">105</xref>)</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Bacillus subtilis spores</td><td valign="top" align="left" rowspan="1" colspan="1">Balb/c<break/>mice</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant protein of P. falciparum CSP<break/>(rPfCSP)</td><td valign="top" align="left" rowspan="1" colspan="1">rPfCSP coupled to B. subtilis spores/10ug per dose/intranasally vaccinated on days 0, 14 and 21</td><td valign="top" align="left" rowspan="1" colspan="1">Elevated serum IgG levels, especially IgG2b levels, and induced a balanced Th1/Th2 immune response</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B116" ref-type="bibr">116</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6 mice</td><td valign="top" align="left" rowspan="1" colspan="1">C fragment of the tetanus toxin (TTFC)</td><td valign="top" align="left" rowspan="1" colspan="1">Spore-adsorbed TTFC/2.0&#x000d7;10<sup>9</sup> spore-adsorbed with 2.0 &#x000b5;g of TTFC in a volume of 20 &#x000b5;l of 50 mM Sodium Citrate buffer/vaccinated by the intranasal route on day 0 and received a booster on days 14 and 28</td><td valign="top" align="left" rowspan="1" colspan="1">Increased sIgA production, accelerated the production of serum IgG</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B119" ref-type="bibr">119</xref>)</td></tr></tbody></table><table-wrap-foot><fn><p>HpaA, Helicobacter pylori adhesin A; NE, nanoemulsion; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; IVT DI, an RNA agonist of RIG-I; IgA, immunoglobulin A; IgG, immunoglobulin G; rPfCSP, recombinant P. falciparum circumsporozoite surface protein; Th1, type-1 helper T cell; Th2, type-2 helper T cell; TTFC, C fragment of the tetanus toxin; BMDC, Bone Marrow-Derived Dendritic Cells.</p></fn></table-wrap-foot></table-wrap><p>Currently, the majority of clinical research on intranasal vaccines focuses on respiratory diseases such as influenza, RSV (Respiratory Syncytial Virus), COVID-19, and whooping cough (<xref rid="T5" ref-type="table">
<bold>Table&#x000a0;5</bold>
</xref>). Among these, some vaccines incorporate delivery systems such as nanoemulsions, liposomes, VLPs (Virus-Like Particles), and chitosan to enhance the efficacy of antigens. In these studies, influenza vaccines are the most extensively researched and widely applied intranasal vaccines. The primary type is the live attenuated vaccine, which holds significant research value and market potential, and has also spurred the development of other live attenuated vaccines.</p><table-wrap position="float" id="T5"><label>Table&#x000a0;5</label><caption><p>The current progress in clinical studies of intranasal vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Disease</th><th valign="top" align="left" rowspan="1" colspan="1">Interventions</th><th valign="top" align="left" rowspan="1" colspan="1">Delivery system/ adjuvant</th><th valign="top" align="left" rowspan="1" colspan="1">ClinicalTrials. gov Identifier&#x02003;</th><th valign="top" align="left" rowspan="1" colspan="1">Phase&#x02003;</th><th valign="top" align="left" rowspan="1" colspan="1">Sponsor</th><th valign="top" align="left" rowspan="1" colspan="1">Status</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Norovirus</td><td valign="top" align="left" rowspan="1" colspan="1">Norwalk VLP Vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">VLP adjuvanted with MPL and chitosan</td><td valign="top" align="left" rowspan="1" colspan="1">NCT00806962</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">LigoCyte Pharmaceuticals, Inc.</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">HIV</td><td valign="top" align="left" rowspan="1" colspan="1">Vacc-4x</td><td valign="top" align="left" rowspan="1" colspan="1">Endocine</td><td valign="top" align="left" rowspan="1" colspan="1">NCT01473810</td><td valign="top" align="left" rowspan="1" colspan="1">1/2</td><td valign="top" align="left" rowspan="1" colspan="1">Oslo University Hospital</td><td valign="top" align="left" rowspan="1" colspan="1">Completed&#x02003;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ad4-mgag<break/>Ad4-EnvC150<break/>gp 120 Protein Boost</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NCT01989533</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">National Institute of Allergy and Infectious Diseases (NIAID)</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">influenza</td><td valign="top" align="left" rowspan="1" colspan="1">Influnza vaccination</td><td valign="top" align="left" rowspan="1" colspan="1">Liposomes</td><td valign="top" align="left" rowspan="1" colspan="1">NCT00197301</td><td valign="top" align="left" rowspan="1" colspan="1">1/2</td><td valign="top" align="left" rowspan="1" colspan="1">Hadassah Medical Organization</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sing2016<break/>M2SR<break/>H3N2 influenza vaccine</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NCT04785794</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">FluGen Inc</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BW-1014</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoemulsion</td><td valign="top" align="left" rowspan="1" colspan="1">NCT05397119</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">BlueWillow Biologics</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">hemagglutinin (HA)</td><td valign="top" align="left" rowspan="1" colspan="1">AD07010LTh(&#x003b1;K)</td><td valign="top" align="left" rowspan="1" colspan="1">NCT03784885</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">Advagene Biopharma Co. Ltd.</td><td valign="top" align="left" rowspan="1" colspan="1">Completed&#x02003;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">A/California/07/09 live monovalent H1N1 vaccine</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NCT01023776</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">University of Rochester</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Whooping Cough</td><td valign="top" align="left" rowspan="1" colspan="1">Vaccine GamLPV</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NCT04036526</td><td valign="top" align="left" rowspan="1" colspan="1">1/2</td><td valign="top" align="left" rowspan="1" colspan="1">Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown status</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BPZE1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NCT03541499</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">National Institute of Allergy and Infectious Diseases (NIAID)</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Covid19</td><td valign="top" align="left" rowspan="1" colspan="1">MV-014-212</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NCT04798001</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Meissa Vaccines, Inc.</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown<break/>status *</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CVXGA1</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NCT04954287</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">CyanVac LLC</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">RSV</td><td valign="top" align="left" rowspan="1" colspan="1">MV-012-968</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NCT04444284</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Meissa Vaccines, Inc.</td><td valign="top" align="left" rowspan="1" colspan="1">Completed&#x02003;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RSVt Vaccine</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NCT05687279</td><td valign="top" align="left" rowspan="1" colspan="1">1/2</td><td valign="top" align="left" rowspan="1" colspan="1">Sanofi Pasteur, a Sanofi Company</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Tuberculosis</td><td valign="top" align="left" rowspan="1" colspan="1">TB/Flu-05E</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NCT05945498</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Tatyana Zubkova</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TB/Flu-05E</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NCT06873282</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">Research Institute of Influenza, Russia</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Anthrax</td><td valign="top" align="left" rowspan="1" colspan="1">BW-1010</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoemulsion</td><td valign="top" align="left" rowspan="1" colspan="1">NCT04148118</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">BlueWillow Biologics</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Asthma in Children</td><td valign="top" align="left" rowspan="1" colspan="1">LAIV<break/>IIV</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NCT03600428</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">Vanderbilt University Medical Center</td><td valign="top" align="left" rowspan="1" colspan="1">Completed</td></tr></tbody></table><table-wrap-foot><fn><p>VLP, Virus-like particle; HIV, Human immunodeficiency virus; Covid-19, Coronavirus disease 2019; RSV, Respiratory syncytial virus; LAIV, Live attenuated influenza vaccine; IIV, Inactivated influenza vaccine; The data us derived from <uri xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</uri> provided in the websites.</p></fn></table-wrap-foot></table-wrap><p>In this review, we focus on NDDS as advanced carriers for optimizing antigen transport and mucosal retention. While the primary emphasis lies in elucidating mechanistic strategies for targeted delivery, we also examine the combination role of adjuvants. To avoid ambiguity, adjuvants (e.g., TLR agonists, cyclic dinucleotides) is restricted to the components enhancing immune responses although certain adjuvants (e.g., particulate carriers like alum or lipid-based nanoparticles) inherently possess dual functionalities as both immunostimulants and delivery vehicles.</p></sec><sec id="s2"><label>2</label><title>Nanoparticles types used in nasal vaccines</title><sec id="s2_1"><label>2.1</label><title>Polysaccharide: biocompatible and biodegradable polymers for delivery systems</title><p>Polysaccharides represent an exciting class of biomaterials for intranasal vaccine delivery, offering three critical advantages: excellent biocompatibility, predictable biodegradability, and potent immunomodulatory properties (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B22" ref-type="bibr">22</xref>). The most promising polysaccharide platforms include chitosan, starch, maltodextrin, alginate, etc (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>). These innovative materials effectively solve three major challenges in intranasal vaccination: overcoming mucociliary clearance, enhancing epithelial barrier penetration, and providing sustained antigen release (<xref rid="B18" ref-type="bibr">18</xref>), all while maintaining superior safety and stability profiles (<xref rid="B8" ref-type="bibr">8</xref>). Ongoing research continues to unlock their full potential for developing next-generation mucosal vaccines.</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>Structural and functional features of polysaccharide-based intranasal delivery systems. The most promising polysaccharide platforms include chitosan, starch, maltodextrin, alginate and others. Low-toxicity and mucoadhesive chitosan improves antigen transport across mucosal barriers; biodegradable starch microparticles protect antigens from enzymatic breakdown; hydrophilic gel microparticles, alginate, aid in the absorption and retention of mucosal antigens; maltodextrin nanoparticles improve intranasal delivery effectiveness, and they induce Th1/Th17 responses with high tolerability.</p></caption><graphic xlink:href="fimmu-16-1573037-g002" position="float"/></fig><sec id="s2_1_1"><label>2.1.1</label><title>Chitosan</title><p>Chitosan is a naturally occurring, biocompatible linear polysaccharide composed of repeating units of d-glucosamine and N-acetyl-d-glucosamine. It is the product of N-deacetylation of chitin, which is derived from the exoskeletons of crustaceans and insects. Chitosan is a safe and biocompatible cationic polymer that can be degraded by a group of chitinases found in many organisms, including humans (<xref rid="B23" ref-type="bibr">23</xref>). In addition to its safety and biocompatibility, chitosan has been extensively researched for its low toxicity, mucoadhesiveness, immunogenicity, and permeability. The U.S. Food and Drug Administration (FDA) has approved the use of chitosan in foods and pharmaceuticals (<xref rid="B24" ref-type="bibr">24</xref>).</p><p>Nanoparticles (NPs) based on chitosan or chitosan derivatives, ranging in size from 1 to 1000 nanometers have been utilized as promising immune delivery systems, delivering vaccine antigens through mucosal pathways such as the nasal routes. Chitosan nanoparticulate systems are particularly successful as vaccine delivery vehicles due to their positive charge, which can improve antigen absorption and boost cellular uptake. Experiments have revealed that positively charged chitosan nanoparticles tend to adhere to negatively charged mucoproteins, reducing nasal evacuation of the nanoparticles. Additionally, Chitosan and its derivatives have the ability to open tight junctions between epithelial cells, elicit immunological responses, and promote IFN-I production, making them potentially effective immune delivery systems (<xref rid="B25" ref-type="bibr">25</xref>&#x02013;<xref rid="B27" ref-type="bibr">27</xref>).</p><p>In recent years, vaccines based on chitosan or its derivatives as intranasal immune delivery systems have been extensively studied and have been applied in the development of vaccines for infectious disease. For instance, a lentogenic live-virus vaccine (strain LaSota) against newcastle disease virus encapsulated chitosan nanoparticles can elicit robust mucosal immune responses and show a high level of safety in chickens (<xref rid="B28" ref-type="bibr">28</xref>).</p><p>Although chitosan has significant potential for application, it is sensitive to pH: chitosan dissolves readily at lower pH levels but is less soluble at higher pH levels. Since many proteins are unstable at low pH levels, chitosan&#x02019;s pH sensitivity may limit its use in antigen delivery (<xref rid="B29" ref-type="bibr">29</xref>). Therefore, chitosan is typically modified, such as by forming nanoparticles or allowing free amino and carboxyl functional groups in chitosan through various chemical reactions, including carboxylation, esterification, hydroxylation, and acetylation, to make chitosan derivatives (<xref rid="B24" ref-type="bibr">24</xref>).</p><p>Among different chitosan derivatives, quaternization, particularly N-trimethyl chitosan (N-TMC), has received the greatest interest. This is owing to its persistent cationic charge and wide pH solubility range. Even at neutral pH, it exhibits strong mucoadhesive and permeation-enhancing properties (<xref rid="B26" ref-type="bibr">26</xref>). Chen et&#x000a0;al. developed a nanoparticle delivery system, CS/O-HTCC, using the chitosan derivative O-(2-hydroxy) propyl-3-trimethyl ammonium chitosan chloride (O-HTCC) and the &#x003b2;-glucan derivative, curdlan sulfate (CS). They created a nasal mucosal protein subunit vaccine, CS/S-RBD/O-HTCC, using the SARS-CoV-2 spike receptor binding domain (S-RBD) as the antigen, and confirming its safety <italic>in vitro</italic> and <italic>in vivo</italic>. When CS/O-HTCC is loaded with S-RBD mixed antigens (ancestral and omicron), it provoked high levels of ancestral S-RBD specific IgG in serum, sIgA from nasal lavage fluid and antigen-specific IFN-&#x003b3; from splenic lymphocytes, suggesting that CS/S-RBD/O-HTCC could induce robust humoral, mucosal and cellular immunity. For the neutralizing assay, this vaccination could induce neutralizing antibodies against both ancestral and omicron pseudoviruses than those in the groups using single antigens. This delivery vehicle might be utilized to rapidly prepare vaccines against the continuously mutating SARS-CoV-2 virus (<xref rid="B25" ref-type="bibr">25</xref>). In another study, Chen et&#x000a0;al. discovered that nanoparticles formed by coupling sulfated lentinan and O-HTCC, as a nasal H1N1 subunit vaccine delivery carrier can stimulate mice macrophage phagocytosis, promote dendritic cell maturation and activation, enhance the production of antigen-specific sIgA in saliva and vaginal lavage fluid and IgG in serum, indicating promising applications (<xref rid="B30" ref-type="bibr">30</xref>).</p><p>What&#x02019;s more, numerous recent studies have explored the modification of chitosan nanoparticles with other substances, such as ethylene glycol. Dilip Pawar et&#x000a0;al. were the first to synthesize and evaluate glycol chitosan (GC) nanoparticles. In the <italic>in vitro</italic> Calu-3 cell line model, they found that chitosan and GC exhibited minimal toxicity. In comparison to bare chitosan nanoparticles, intranasal treatment of GC nanoparticles loaded with hepatitis B surface antigen (HBsAg) in mice demonstrated better mucoadhesion, which resulted in a substantially lower rate of clearance as compare to chitosan NPs (<xref rid="B31" ref-type="bibr">31</xref>).</p><p>In addition to surface modification of chitosan to enhance the immune response elicited by vaccines, studies have also explored the adjuvant combination to develop more effective vaccine formulations. Dulce Bento developed a co-adjuvant delivery system for intranasal administration of the hepatitis B virus vaccine, combining the mast cell activator C40/80 with chitosan nanoparticles. The delivery system was shown to have promising features for vaccine delivery, such as the ability to adsorb high amounts of antigen, internalization by APCs, and stability after lyophilization, which can be important during the development of designing a cold chain-free vaccine. C48/80 loaded chitosan nanoparticles NPs have the ability to enhance the immune response to HBsAg such as inducing mucosal anti-HBsAg IgA and specific IgG titers in the vaccinated mice compared to free HBsAg and chitosan-poly epsilon caprolactone NPs (<xref rid="B32" ref-type="bibr">32</xref>).</p></sec><sec id="s2_1_2"><label>2.1.2</label><title>Starch</title><p>Starch is a naturally biocompatible and biodegradable polymer. There are two different types of starch: amylose and amylopectin. Most starch consists of ~20% amylose and ~80% amylopectin. While amylose and amylopectin are readily degraded by &#x003b1;-amylase, starch remains insoluble in water (<xref rid="B33" ref-type="bibr">33</xref>). Starch microparticles can be utilized as a vaccine carrier because it prevents the denature of antigen proteins by temporarily protecting antigens from the acidic and enzymatic environment of mucosal surfaces (<xref rid="B34" ref-type="bibr">34</xref>). Protein molecules can be encapsulated and coupled into particles made of modified and cross-linked starch. Starch can be shaped in a variety of forms, including Spherex microparticles, polyacryl starch microparticles, silicone-grafted starch microparticles, and more (<xref rid="B33" ref-type="bibr">33</xref>). Studies have shown that macrophages stimulated by starch in the form of granules release IL-1 (<xref rid="B35" ref-type="bibr">35</xref>). In the meantime, mice immunized intranasally with an antigen and silicone-polymer-grafted starch microparticle system likewise produced a robust circulating IgG responses (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B36" ref-type="bibr">36</xref>).</p><p>Pullulan, a microbial exopolysaccharide generated by <italic>Aureobasidium pullulans</italic>, is a highly biocompatible and biodegradable polymer that is odorless, tasteless, non-toxic and edible. It has maltotriose repeating units and is a linear, unbranched polymer chain structurally (<xref rid="B37" ref-type="bibr">37</xref>). A nanogel particle consisting of a cholesterol-bearing pullulan has been proposed as an intranasal delivery system (<xref rid="B38" ref-type="bibr">38</xref>). Charge-based interaction can be employed to make the particles stick to the nasal epithelium and release antigens since the particles have a positive charge while the mucosa has a negative charge (<xref rid="B39" ref-type="bibr">39</xref>). This mechanism can slow the release of antigens and prolong the existence time of antigens in the nasal mucosa (<xref rid="B40" ref-type="bibr">40</xref>). The antigen can be efficiently delivered to the nasal epithelium, where it is then taken up by dendritic cells. A protective immune response against <italic>Streptococcus pneumoniae</italic> was induced in mice after they were intranasally immunized with a vaccine conjugated with pneumococcal surface protein A using a cationic cholesteryl-group-bearing pullulan nanogel as a delivery system. This resulted in an increased production of serum PspA-specific IgG1 antibodies, high levels of mucosal antigen-specific sIgA antibodies, Th17 and Th2 responses, and the growth of bacteria in the mice&#x02019;s lungs and nasal cavities was inhibited (<xref rid="B41" ref-type="bibr">41</xref>). Furthermore, the vaccine was administered to rhesus macaques, a non-human primate species. It not only induced systemic and mucosal antibody responses in the macaques, but it also prevented the antigen from being deposited in their brains or olfactory bulbs, making it safe (<xref rid="B42" ref-type="bibr">42</xref>). A recent study investigated the utilization of pullulan-bearing cholesterol moieties in nanogel particles as a delivery system. The delivery system induced antigen-specific serum IgG and nasal mucosal IgA by intranasally immunizing mice with pneumococcal surface protein A as an antigen (<xref rid="B43" ref-type="bibr">43</xref>).</p></sec><sec id="s2_1_3"><label>2.1.3</label><title>Maltodextrin</title><p>Maltodextrin (MD) is a natural polysaccharide derived from partially hydrolyzed starch. Maltodextrin-based nanoparticles, known as supramolecular biovectors (SMBVs) and cationic porous maltodextrin nanoparticles (NPLs), can be mixed with lipids to be employed as intranasal delivery systems (<xref rid="B44" ref-type="bibr">44</xref>).</p><p>After intranasal immunization, lipid-coated SMBVs with maltodextrin scaffolds cling to the mucosa continuously, enhancing intranasal antigen delivery and inducing systemic and mucosal immunological responses, such as antibody production and Th1 and Th2 immune responses (<xref rid="B45" ref-type="bibr">45</xref>). The efficacy of SMBV-based nasal influenza vaccinations was demonstrated in a dose-escalation clinical trial that was randomized, placebo-controlled, and conducted on healthy individuals. The vaccines produced mucosal immune responses and were well tolerated with moderate immunogenicity (<xref rid="B46" ref-type="bibr">46</xref>).</p><p>With anionic lipids contained in the maltodextrin scaffold as the core, Maltodextrin nanoparticles (MdNP) is a porous cationic maltodextrin scaffold and has been investigated as nasal route delivery methods for antigens and medications (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>). Regarding the safety of maltodextrin, numerous <italic>in vivo</italic> and <italic>in vitro</italic> tests have demonstrated that MdNP is safe since it is unable to penetrate the nasal mucosal epithelial barrier (<xref rid="B48" ref-type="bibr">48</xref>). When compared to other nanoparticle delivery systems, MdNP also had the longest residence duration in dendritic cells, macrophages, and airway epithelial cells, the highest endocytosis efficiency, and the strongest antigen delivery effect (<xref rid="B49" ref-type="bibr">49</xref>). The immune response induced by MdNP is dominated by Th1/Th17 (<xref rid="B44" ref-type="bibr">44</xref>). MdNP has been utilized to prevent acute or chronic toxoplasma gondii infection (<xref rid="B50" ref-type="bibr">50</xref>). According to a recent study, mice inoculated with the MdNP formulations were not only protected against infection, but also did not transmit the influenza virus (<xref rid="B51" ref-type="bibr">51</xref>).</p></sec><sec id="s2_1_4"><label>2.1.4</label><title>Alginate</title><p>Alginate is the basic carbohydrate component of brown algae. It is an unbranched copolymer with the qualities of hydrophilicity, adhesion, biocompatibility and biodegradability (<xref rid="B52" ref-type="bibr">52</xref>&#x02013;<xref rid="B54" ref-type="bibr">54</xref>). Gel microparticles are formed when most bivalent cations are added to alginate solutions (<xref rid="B52" ref-type="bibr">52</xref>). The resulting microparticles are irregular in shape, have a rough and porous surface, and a high polypoid structure. These particles can develop under more hospitable settings (<xref rid="B55" ref-type="bibr">55</xref>). Their benefits include being inexpensive and non-toxic at the same time (<xref rid="B52" ref-type="bibr">52</xref>). Alginate has strong adhesion and can extend the duration of contact between microparticles and M cells, hence augmenting antigen absorption (<xref rid="B55" ref-type="bibr">55</xref>). By activating macrophage-like cells through the NF-&#x003ba;B pathway, alginate can trigger an innate immune response (<xref rid="B56" ref-type="bibr">56</xref>). Alginate microparticles have been employed in the creation of Klebsiella pneumoniae vaccines (<xref rid="B55" ref-type="bibr">55</xref>).</p><p>Alginate nanoparticles are often negatively charged, and mucus on the mucosal surface is similarly negatively charged, so this makes it unsuitable for substance delivery. Chitosan and alginate are frequently used in combination because the inclusion of chitosan enhances the positive charge on the particle surface while also enhancing the immunostimulatory qualities and stability of chitosan (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B57" ref-type="bibr">57</xref>). Chitosan/alginate nanoparticle encapsulated bee venom (BV), CH/AL-BV, has slow-releasing properties and mucosal adhesiveness. Nasal delivery of CH/AL-BV in pigs enhanced Th1-related responses, porcine reproductive and respiratory syndrome virus (PRRSV)-specific viral neutralizing antibody and significant reductions in PRRSV load in serum, lung and bronchial lymph nodes (<xref rid="B54" ref-type="bibr">54</xref>). Recently, nasal immunization of mice with trimethylchitosan nanoparticles containing influenza virus coated with sodium alginate induced a significant increase in the IgG2a/IgG1 ratio and improved immune protection against the virus (<xref rid="B57" ref-type="bibr">57</xref>). The combination of chitosan and alginate nanoparticles has the potential to be a highly effective vaccine delivery system.</p><p>Hyaluronic acid and dextran are other polysaccharides that can be also utilized as vaccine delivery platform. As a nanoparticle vaccine delivery system, a biodegradable polymer micellar coated with hyaluronic acid was created. Ovalbumin and adjuvant CpG-DNA were loaded onto the micellar, increasing the expression of MHC-II also IFN-&#x003b3; and IL-4 mRNA expression in mouse dendritic cells. Correspondingly, nasal immunization resulted in higher antigen-specific serum IgG and nasal IgA levels (<xref rid="B58" ref-type="bibr">58</xref>).</p></sec></sec><sec id="s2_2"><label>2.2</label><title>PLGA: a promising and thriving mediators for delivery system</title><p>PLGA, poly (lactic-co-glycolic acid), is a biodegradable polymer consisting of lactic acid and glycolic acid linked via ester linkages. PLGA is soluble in common solvents such as acetone, chlorinated solvents, and ethyl acetate, and can be processed into virtually any shape and size, and encapsulated into various molecules (<xref rid="B59" ref-type="bibr">59</xref>). PLGA nanoparticles are one of the most widely used particles, having been used in a wide range of cosmetic, food, agricultural, and drug delivery systems (<xref rid="B60" ref-type="bibr">60</xref>).</p><p>Among vaccine delivery systems, PLGA is commonly used to protect peptide vaccines from degradation, enhance antigen absorption by APCs, and stimulate robust T cell immune responses (<xref rid="B61" ref-type="bibr">61</xref>). Furthermore, PLGA nanoparticle vaccines allow for a sustained release of antigen, which is essential for the duration and intensity of the induced vaccine response. Since PLGA nanoparticles are biodegradable, biocompatible, and non-toxic, they have been approved for many biomedical applications, with the U.S. FDA approving them as sustained-release drug delivery systems (<xref rid="B62" ref-type="bibr">62</xref>).</p><p>B&#x000fc;y&#x000fc;kbayraktar et&#x000a0;al. developed an anti-tuberculosis vaccine with polycation-coated PLGA nanoparticles as delivery system, a potential vaccine model for long-term pulsatile release of antigenic peptide of ESAT-6 protein of M. tuberculosis, which augment the immunostimulation and also allows to be administered via nasal route. Using <italic>in vitro</italic> model of murine macrophage cell line (J774) and human macrophage cell line (THP-1), the peptide-loaded nanoparticle enhanced the immunogenicity of the peptides to induce more nitric oxide (NO) than the free peptide and non-coated nanoparticle, demonstrating the immunostimulant activity of the nanoparticle systems. They also discovered that the macrophages exposure to these formulations maintained their intact structure without any cytotoxic effects (<xref rid="B63" ref-type="bibr">63</xref>).</p><p>Additionally, a number of studies using a model antigen such as tetanus or diphtheria confirmed the potent adjuvant effect of PLGA, which connected with their capacity to be effectively taken up by APCs (<xref rid="B61" ref-type="bibr">61</xref>). Many studies also tend to surface-modify it which can help them evade the body&#x02019;s defense system, and make vaccines safer and more efficient through nasal immunization, a non-invasive route (<xref rid="B59" ref-type="bibr">59</xref>).</p></sec><sec id="s2_3"><label>2.3</label><title>Gold nanoparticles (AuNPs) can capture and retain antigenic epitopes</title><p>Gold nanoparticles (AuNPs) represent one of the most widely studied metallic nanomaterials, which typically range in size from 1 nm to 100 nm, which may be beneficial in overcoming biological barriers (<xref rid="B64" ref-type="bibr">64</xref>). It is available in various types such as gold nanorods, nanocages, nanostars, nanocubes and nanospheres, and the type and size of the nanoparticles affect their physical characteristics and surface functionalization (<xref rid="B65" ref-type="bibr">65</xref>). Gold nanoparticles are widely used in the biomedical field due to their small size-to-volume ratio, functionalization, stability, low toxicity, and ease of detection, and they can bind to a variety of functionalized fractions through different types of interactions, including ligands, medicinal agents, DNA, amino acids, proteins, peptides, and oligonucleotides (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>).</p><p>Gold nanoparticles can capture and retain antigenic epitopes and improve the efficiency of antigen delivery and presentation. By studying different shapes of gold nanoparticles, Hongjuan Zhao et&#x000a0;al. found that star-shaped AuNPs captured and retained more repetitive antigenic epitopes and triggered a strong humoral immune response mediated by the cooperation of CD4<sup>+</sup> T helper cells and follicular B cells, whereas caged AuNPs caused a strong CD8<sup>+</sup> T cell immunity (<xref rid="B68" ref-type="bibr">68</xref>).</p><p>Immunoreactivity of a DNA vaccine expressing the SARS-CoV-2 spike (S) protein on gold chitosan nanocarriers reveals a sustained surge in antibodies (IgG, IgA, and IgM) (<xref rid="B69" ref-type="bibr">69</xref>). In addition, coupling lipopolysaccharide (LPS) from Bacillus thailandensis with AuNPs for intranasal immunization of mice, which promote robust antigen-specific antibody responses (<xref rid="B70" ref-type="bibr">70</xref>).</p></sec><sec id="s2_4"><label>2.4</label><title>Nanogels can retain the hydrated nature and shrink-swell properties of hydrogels</title><p>Nanogels are drug delivery vehicles with three-dimensional tunable porous structures with particle sizes in the submicron range, from 20 to 250 nm (<xref rid="B71" ref-type="bibr">71</xref>). It is formed by a system of chemically or physically cross-linked swellable polymer networks, which help encapsulate small molecules, oligonucleotides and even proteins while maintaining their structural integrity (<xref rid="B72" ref-type="bibr">72</xref>). As a hydrogel, nanogels can retain the highly hydrated nature and shrink-swell properties of hydrogels under different conditions, and these unique properties give nanogels the ability to enable drug delivery, diagnostics, and imaging (<xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B73" ref-type="bibr">73</xref>). Unlike typical nanoparticles, nanogels exhibit tunable particle size, particle shape, and sensitivity to pH, temperature, ionic strength, redox conditions, and other external stimuli. Nanogels have a pronounced spherical structure, and with the latest advances in their fabrication processes can also be produced in a variety of nanogel types, allowing for effective controlled drug release properties (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B75" ref-type="bibr">75</xref>).</p><p>Nanogel consisting of self-assembled cholesteryl group-bearing pullulan (CHP) has strong advantages as a novel adjuvant-free and safe carrier for mucosal vaccines. For example, nasal administration of nanogels containing subunit types of botulinum antigen (BoHc-nanogel) or pneumococcal surface protein A (PspA-nanogel) enhance antigen-specific systemic and mucosal immune responses, even in the absence of biologically active mucosal adjuvants (e.g., CT) (<xref rid="B38" ref-type="bibr">38</xref>).</p><p>Gel system consisting of glutamine and benzaldehyde derivatives combined with extracellular vesicles derived from mouse aortic endothelial cells has better absorption efficiency in the nasal cavity and reduces levels of pro-inflammatory Ly6C<sup>hi</sup> monocytes/macrophages and neutrophils (<xref rid="B76" ref-type="bibr">76</xref>). Y Fukuyama et&#x000a0;al. established a nanosized nasal vaccine delivery system by using a cationic cholesterol group-bearing pullulan nanogel (cCHP nanogel) in a study examining the central nervous system safety and efficacy of nasal vaccination with their developed cCHP nanogel containing pneumococcal surface protein A (PspA-nanogel) against pneumococcal infection in nonhuman primates, demonstrating that nasal PspA-nanogel vaccination is a safe and effective strategy for the development of a nasal vaccines for the prevention of pneumonia in humans (<xref rid="B41" ref-type="bibr">41</xref>).</p></sec><sec id="s2_5"><label>2.5</label><title>Lipopeptides: self-assembly structure and efficient immune response</title><p>Lipopeptides are mixtures of lipids and peptides that have the ability to self-assemble into the structures of nanoparticles in an aqueous environment. The interaction or balance between the hydrophilic and lipophilic qualities of lipids and peptides determines the lipopeptides&#x02019; ability to self-assemble (<xref rid="B77" ref-type="bibr">77</xref>). Lipopeptides are used as delivery systems in nasal vaccines primarily to prevent rheumatic fever and rheumatic heart disease, which are significant respiratory infections caused by Group A streptococcus (GAS), which makes it an ideal delivery system, suitable for both mucosal and systemic immunization (<xref rid="B78" ref-type="bibr">78</xref>).</p><p>Because of their small nanosize structure and shape, lipopeptide vaccines are well absorbed by APCs and trigger a robust immune response and employed as a nasal vaccination to prevent GAS infection. For instance, the LP-88/30-J14 lipopeptide vaccine (containing both the N-terminal and C-terminal epitope of GAS) has a higher IgG titer and APC uptake of antigen due to its smaller nanosize, which increases the uptake of M protein antigen by DC, in comparison to LP-88/30 (N-terminal epitope) and LP-J14 (C-terminal epitope) alone (<xref rid="B79" ref-type="bibr">79</xref>).</p></sec><sec id="s2_6"><label>2.6</label><title>Liposomes enhance the delivery of antigens to antigen-presenting cells</title><p>Lipid nanoparticles are submicron capsules with an aqueous core, such as liposomes, micelles, or nanoparticles with oil, solid, or a non-crystalline core surrounded and stabilized by a lipid layer, e.g., nucleic acid-containing lipid nanoparticles (commonly referred to as LNP) (<xref rid="B80" ref-type="bibr">80</xref>). Among them, liposomes are safe, biocompatible, biodegradable spherical nanoparticles composed of cholesterol and phospholipids that can be loaded with both hydrophilic and lipophilic molecules, and these properties make liposomes good gene, drug, and vaccine delivery systems (<xref rid="B81" ref-type="bibr">81</xref>). Liposomes can be cationic, anionic, or neutral, depending on the phospholipids that make up the liposome. Phospholipids are amphiphilic molecules with hydrophilic heads and lipophilic tails, and the surface charge of liposomes depends on the phospholipid head group (<xref rid="B82" ref-type="bibr">82</xref>). Depending on the nature of the loaded substance, liposomes can be loaded with drugs or antigens in two ways, either by encapsulating a water-soluble substance in a hydrophilic core or by containing a lipid-soluble substance in the hydrophobic space of a bilayer lipid membrane (<xref rid="B82" ref-type="bibr">82</xref>).</p><p>Liposomes enhance the delivery of antigens to antigen-presenting cells and co-deliver antigens with adjuvants, thereby increasing vaccine efficacy and enhancing immunogenicity (<xref rid="B83" ref-type="bibr">83</xref>). Cationic liposomes are widely used for gene and protein delivery. Cationic liposomes have been used in nasal immunization (<xref rid="B84" ref-type="bibr">84</xref>). Cationic DOTAP/DC-chol liposomal complex OVA drops preferentially induced the Th2 response after nasal immunization and enhanced OVA uptake by CD11c<sup>+</sup> DCs in nasal-associated lymphoid tissues (<xref rid="B85" ref-type="bibr">85</xref>). In addition, it has also been shown that immunization with cationic liposomes complexed with antigen followed by nasal drops enhances antigen-specific mucosal IgA responses by inducing IL-6 expression. Intranasal liposomal vaccine delivery induces a mucosal response in the respiratory system and a systemic immune response that produces IgA and systemic IgG (<xref rid="B86" ref-type="bibr">86</xref>).</p><p>In addition, polymeric micelles are considered good carriers for drug delivery due to their stability, nanosize, surface properties, and enhanced permeability and retention effects (<xref rid="B87" ref-type="bibr">87</xref>). The hydrophobic core of the micelles consists mainly of polyester, poly (L-amino acids) and polycaprolactone, and the hydrophilic shell consists mainly of polyethylene glycol (PEG), with sizes ranging from 10 to 100 nanometers (<xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B89" ref-type="bibr">89</xref>). Polymeric micelle-based antigen delivery systems were developed for bacterial pathogens. Shaobin Shang et&#x000a0;al. loaded mycolic acid (MA), a lipid components of Mycobacterium tuberculosis (Mtb) cell wall, into micellar nanocarriers (MA-Mc), which elicited a CD1b-restricted T cell response in the lungs after intranasal immunization of mice, demonstrating that MA-Mc can be explored as subunit vaccines against Mtb infection (<xref rid="B90" ref-type="bibr">90</xref>). Kengo Suzuki et&#x000a0;al. found that hyaluronic acid (HA)-coated micelles can efficiently deliver antigens and adjuvants to mucosal resident immune cells, and that HA-coated micelles are a promising platform for the development of nasal vaccines against infectious diseases (<xref rid="B58" ref-type="bibr">58</xref>).</p></sec><sec id="s2_7"><label>2.7</label><title>VLPs can be easily detected by immune system cells</title><p>Virus-like particles (VLPs) are multimeric self-assembled particles made up of one or more structural proteins that lack viral genetic material, making them incapable of infecting the host cell (<xref rid="B91" ref-type="bibr">91</xref>). As in the case of virus capsids, the antigenic proteins of VLPs self-assemble into highly symmetrical and strict architectures, usually icosahedral and octahedral, with the most of VLPs&#x02019; size ranging from 20-200nm (<xref rid="B92" ref-type="bibr">92</xref>). Virus-like particles can be produced using a variety of expression systems (ESs) without the requirement to propagate pathogenic viruses. The ESs include bacteria, yeast, insect cell lines, plants, mammalian cell lines and cell-free ESs (<xref rid="B92" ref-type="bibr">92</xref>). VLPs are used for a variety of purposes. Because they contain an internal cavity, they can be used as carriers for the delivery of bio- and nanomaterials, including drugs, vaccines, quantum dots and imaging substances (<xref rid="B93" ref-type="bibr">93</xref>). Using VLPs as a delivery strategy has numerous benefits, including precise targeting, biocompatibility, and biodegradability (<xref rid="B94" ref-type="bibr">94</xref>).</p><p>Vaccines based on virus-like particles have gained popularity due to their high immunogenicity. Because of their underlying geometry, VLPs resemble pathogen-associated structural patterns (PASP), which are easily detected by immune system cells (<xref rid="B93" ref-type="bibr">93</xref>). As a result, VLPs are excellent for cellular phagocytosis and antigen presentation of dendritic cells (DCs), eliciting both robust cellular and humoral immune responses even without an adjuvant (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B95" ref-type="bibr">95</xref>).</p><p>To date, numerous perilous viral pathogens have been mimicked by VLPs, including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); Hand, foot and mouth disease virus. Authorized VLP vaccines against hepatitis B virus (HBV), hepatitis E virus (HEV), and human papillomavirus (HPV) are globally used and many others are in clinical trials (<xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B96" ref-type="bibr">96</xref>). VLPs are readily absorbed by APCs, particularly DCs, which improves interactions with NALT. Furthermore, VLP-based intranasal vaccinations can efficiently boost mucosal immune responses, hence reducing viral shedding and local transmission (<xref rid="B97" ref-type="bibr">97</xref>). These benefits have made VLP-based vaccinations popular in the development of intranasal vaccines. Rothen et&#x000a0;al. described a COVID-19 vaccine based on virus-like particles (VLPs) for intranasal administration. Intranasal delivery of the CuMV<sub>TT</sub>-RBD vaccine induces robust local and systemic immune responses, generating high-avidity antibodies with broad-spectrum neutralization against SARS-CoV-2 and its variants of concern (VOCs) in a murine model. This work establishes a foundational framework for advancing next-generation mucosal COVID-19 vaccines designed to block viral entry at respiratory portals while curbing transmission (<xref rid="B98" ref-type="bibr">98</xref>).</p></sec></sec><sec id="s3"><label>3</label><title>Nanoemulsion enhances adhesion and immune response</title><p>Nanoemulsion (NE) is composed of water in oil (W/O) or oil in water (O/W), surfactants and cosurfactants, with an average droplet diameter of less than 500nm. Long-chain triglycerides (LCT) and medium-chain triglycerides (MCT) are the two categories of commonly utilized oils (<xref rid="B99" ref-type="bibr">99</xref>). Ionic and non-ionic surfactants are the two categories of commonly used surfactants. Non-ionic surfactants include Tween, Span, Poloxamer, etc., while ionic surfactants include Cetylpyridinium Chloride (CPC), Benzalkonium Chloride (BCI), etc (<xref rid="B100" ref-type="bibr">100</xref>).</p><p>Nanoemulsion with good adhesion enhances the duration of antigen residency in the nasal cavity, hence increasing the capacity of APC to absorb antigens and potently stimulating the immune system. The physical and chemical characteristics of surfactants may be connected to the robust NE adherence to mucosa. The cationic surfactant CPC interacts with the negatively charged mucin and the non-ionic surfactant Tween interacts with the mucin due to its hydrophilicity, both of which can make NE firmly adhere to the surface of nasal mucosa, promote the uptake of antigen by nasal epithelial cells, and thus enhance the specific humoral immune response (<xref rid="B100" ref-type="bibr">100</xref>).</p><p>NE such as MF59 and W<sub>80</sub>5EC are used for intranasal immunization. MF59, an oil-in-water emulsion (O/W), is primarily used for influenza vaccine (<xref rid="B101" ref-type="bibr">101</xref>). A W<sub>80</sub>5EC-based influenza vaccine has been successfully tested in a Phase 1 randomized, controlled, observer blind clinical trial, showing a good safety profile in healthy adult volunteers, and induced systemic and mucosal immunity after a single intranasal vaccination (<xref rid="B102" ref-type="bibr">102</xref>). Furthermore, in mice, rats, and guinea pigs, the NE-based hepatitis B vaccine has demonstrated significant immunogenicity and good safety (<xref rid="B103" ref-type="bibr">103</xref>). According to research on vaccines against Helicobacter pylori infection, NE vaccine has high delivery efficiency and no obvious cytotoxicity, induces effective specific Th1 response, reduces the colonization of Helicobacter pylori (<xref rid="B104" ref-type="bibr">104</xref>). One study has developed an adjuvant integrating NE that activates TLR2/4 and NLRP3 with an RNA agonist of RIG-I (IVTDI). The spike protein vaccine incorporating NE/IVD significantly enhances a Th1-biased cellular immune response and elicits high neutralizing antibody titers (<xref rid="B105" ref-type="bibr">105</xref>).</p><p>Recently, a new nano-adjuvant, O/ILNE, consisting of an ionic liquid of choline (+) and niacin (&#x02013;) instead of water. In contrast to MF59 emulsion (O/W), O/IL NE has been shown to increase mucosal IgA, systemic IgG, and cellular immunity. Therefore, the prolonged retention of antigens in the nasal cavity and improved paracellular transport of antigens to the submucosa make it an incredibly effective delivery strategy (<xref rid="B106" ref-type="bibr">106</xref>).</p></sec><sec id="s4"><label>4</label><title>Probiotics in intranasal delivery system</title><p>The WHO defines probiotics as living microorganisms which administered in adequate amounts confer a health benefit on the host (<xref rid="B107" ref-type="bibr">107</xref>). Good safety, adherence, and availability make probiotics highly promising for use in vaccine administration (<xref rid="B108" ref-type="bibr">108</xref>, <xref rid="B109" ref-type="bibr">109</xref>).</p><sec id="s4_1"><label>4.1</label><title>Bacterial spores: a stable and effective mucosal vaccine delivery system</title><p>Bacillus spores can be used as mucosal vaccine carriers (<xref rid="B110" ref-type="bibr">110</xref>). Among them, <italic>Bacillus subtilis</italic> spores have the advantages of thermal stability, and non-pathogenicity and can be used as a vaccine delivery system (<xref rid="B111" ref-type="bibr">111</xref>). <italic>Bacillus subtilis</italic> is a Gram-positive non-pathogenic and endospore-forming bacterium (<xref rid="B112" ref-type="bibr">112</xref>). <italic>Bacillus subtilis</italic> spores can sprout, develop, and revert to mature bacteria when the surrounding conditions are right (<xref rid="B113" ref-type="bibr">113</xref>). The resistance and stability of the spore are determined by its unique structure (<xref rid="B110" ref-type="bibr">110</xref>). Chromosome copies are found in the spore&#x02019;s core, which is encased and shielded by a protein shell and peptidoglycan (<xref rid="B110" ref-type="bibr">110</xref>). Isticato R et&#x000a0;al. reported that mutant spores with modified shells are better at absorbing antigens than spores of the wild type (<xref rid="B114" ref-type="bibr">114</xref>). <italic>Bacillus subtilis</italic> spores can activate innate immunity via TLRs and promote DC maturation and NK cell recruitment. Intranasal immunization of spores absorbed with antigen increased the uptake of antigen, raises cytokine levels and sIgA levels, and conferred protection against viral challenge (<xref rid="B114" ref-type="bibr">114</xref>, <xref rid="B115" ref-type="bibr">115</xref>).</p><p>Recently, a study using <italic>Bacillus subtilis</italic> spores coupled with Plasmodium falciparum recombinant protein to intranasally immunize mice showed that the spores increased the immunogenicity of the antigen and induced higher levels of serum IgG (<xref rid="B116" ref-type="bibr">116</xref>). Studies have also been conducted to create vaccines against C. difficile (Clostridioides difficile) spores by adsorbing C. difficile spore surface proteins to <italic>Bacillus subtilis</italic> spores (<xref rid="B117" ref-type="bibr">117</xref>, <xref rid="B118" ref-type="bibr">118</xref>). Furthermore, studies that adsorbed tetanus toxin to <italic>Bacillus subtilis</italic> spores and immunized mice intranasally showed that spore treatment increased tetanus toxin-specific sIgA production and resulted in more rapid serum IgG production (<xref rid="B119" ref-type="bibr">119</xref>).</p></sec><sec id="s4_2"><label>4.2</label><title>Others</title><p>Apart from <italic>Bacillus subtilis</italic> spores, mucosal vaccines can also be delivered intranasally via Escherichia coli and Lactic acid bacteria. Some studies have constructed <italic>Escherichia coli</italic> expressing allergens and demonstrated that intranasal pretreatment with this <italic>Escherichia coli</italic> before multiple sensitization in mice can significantly reduce allergen-specific serum IgE levels and lung inflammation (<xref rid="B120" ref-type="bibr">120</xref>). Lactic acid bacteria are a group of Gram-positive, non-sporogenic bacteria, including Lactobacillus, Lactococcus, etc (<xref rid="B121" ref-type="bibr">121</xref>). Pneumococcus and tetanus vaccinations have been developed using lactic acid bacteria as a delivery system to stimulate a favorable immune response (<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B123" ref-type="bibr">123</xref>).</p></sec></sec><sec id="s5"><label>5</label><title>Limitations and safety concerns of intranasal vaccine delivery system</title><p>While intranasal vaccines offer significant advantages, their development and application are constrained by anatomical, physiological, and technical challenges.</p><sec id="s5_1"><label>5.1</label><title>Anatomical and physiological risks</title><p>The nasal cavity&#x02019;s proximity to the central nervous system poses unique risks. The thin olfactory epithelium-blood-brain barrier raises concerns about neurotoxic effects if vaccine components inadvertently enter the brain. For instance, mild adverse effects such as rhinorrhea and nasal congestion are common, while severe complications&#x02014;though rare&#x02014;have been documented (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B125" ref-type="bibr">125</xref>). A notable example is the NasalFlu vaccine (approved in Switzerland in 2001), which was withdrawn due to reports of Bell&#x02019;s palsy in immunized individuals (<xref rid="B126" ref-type="bibr">126</xref>).</p></sec><sec id="s5_2"><label>5.2</label><title>Technical limitations of delivery systems</title><p>Current delivery platforms face three major hurdles: (i) Inefficient Antigen Release: Many carriers, such as PLGA nanoparticles, exhibit incomplete antigen release and cannot undergo sterile filtration, limiting their clinical scalability (<xref rid="B127" ref-type="bibr">127</xref>). (ii) Manufacturing Complexity: Materials like chitosan require chemical modification to improve water solubility and biocompatibility, adding to production costs (<xref rid="B128" ref-type="bibr">128</xref>). (iii) Carrier-Related Toxicity: Certain formulations, including cationic liposomes, may induce dose-dependent inflammation, genotoxicity, or cell membrane disruption (<xref rid="B129" ref-type="bibr">129</xref>, <xref rid="B130" ref-type="bibr">130</xref>).</p></sec><sec id="s5_3"><label>5.3</label><title>Safety evidence from preclinical studies</title><p>Emerging preclinical data highlight potential safety issues: (i) Chitosan-based nanoparticles have shown dose-dependent developmental toxicity in zebrafish embryos, including reduced hatching rates, increased malformations, and neurobehavioral abnormalities (<xref rid="B131" ref-type="bibr">131</xref>). (ii) Acylated starch nanoparticles exhibit moderate cytotoxicity at high concentrations, though low doses remain tolerable (<xref rid="B132" ref-type="bibr">132</xref>). (iii) PLGA particles may trigger local immune overactivation if antigen release kinetics are poorly controlled (<xref rid="B127" ref-type="bibr">127</xref>). Despite these challenges, systematic safety evaluations remain limited, underscoring the need for standardized toxicity assays and long-term monitoring in future studies.</p></sec></sec><sec sec-type="conclusions" id="s6"><label>6</label><title>Conclusions</title><p>Intranasal immunization is a safe, effective, and convenient route of mucosal immunization. The nasal cavity itself, with its enormous surface area and specialized immunological tissue (NALT), is an efficient entry channel for vaccinations, making intranasal immunization promising for the mucosal routes. However, intranasal cilia clearance, mucus barrier, and enzyme milieu which make intranasal delivery of antigens challenging. Various intranasal delivery technologies, such as nanoparticles and nanoemulsions, have been created to improve vaccine distribution, increase antigen penetration, and elicit more robust immune responses to solve these problems (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3</bold>
</xref>). Among diverse types of delivery system, nanoparticles especially chitosan nanoparticles are well-studied and offer a promising delivery strategy for promoting antigen uptake and lowering unfavorable vaccine reactions. Despite the promising results in animal models, clinical findings were limited. Therefore, further studies are needed to evaluate the efficiency and safety of these delivery system in human studies. With advances in delivery technologies such as nanoparticles, the challenges of antigen degradation and malabsorption can be mitigated, which may lead to more efficient and broader vaccination strategies. Furthermore, combining advanced delivery systems with adjuvants including STING-activating (e.g., CDNs) could represent a powerful strategy to amplify mucosal immunity. Co-delivery of antigens and adjuvants within nanocarriers may ensure spatiotemporal synchronization of antigen presentation and innate immune activation, thereby enhancing vaccine efficacy. These advances have the potential to increase vaccine efficacy and acceptance, particularly in the prevention of respiratory infections such as influenza, respiratory syncytial virus and coronavirus, and will play an increasingly critical role in global vaccination campaigns and contribute to improved global public health outcomes.</p><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>Schematic overview of intranasal vaccine delivery system against infectious disease. The outer blue segment and the green segment in the middle represents the key outcome induced by and the diagram of intranasal delivery system, respectively. Polysaccharides stimulate dendritic cell maturation and natural killer cell recruitment through TLR ligation. Nanoemulsions enhance antigen uptake in antigen-presenting cells. Lipopeptides boost APC absorption and activate potent immune responses. Liposomes optimize antigen delivery efficiency. Probiotics strengthen host health. Virus-like particles inhibit viral shedding and curb local transmission. Nanogels suppress pro-inflammatory Ly6C hi levels. Au nanoparticles elicit robust CD8<sup>+</sup> T cell immunity. PLGA nanoparticles amplify antigen immunogenicity.</p></caption><graphic xlink:href="fimmu-16-1573037-g003" position="float"/></fig></sec></body><back><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>ZZh: Conceptualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing, Data curation, Formal Analysis, Investigation, Methodology, Visualization. YY: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Visualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. LH: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Visualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. LY: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Visualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. SH: Investigation, Writing &#x02013; review &#x00026; editing. ZZe: Investigation, Writing &#x02013; review &#x00026; editing. YC: Investigation, Writing &#x02013; review &#x00026; editing. XHW: Investigation, Writing &#x02013; review &#x00026; editing. XMW: Writing &#x02013; review &#x00026; editing, Conceptualization, Supervision, Validation. MS: Conceptualization, Supervision, Validation, Writing &#x02013; review &#x00026; editing. MZ: Conceptualization, Funding acquisition, Project administration, Supervision, Validation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meng</surname><given-names>QY</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Cong</surname><given-names>HL</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>FJ</given-names></name></person-group>. <article-title>An overview of chitosan and its application in infectious diseases</article-title>. <source>Drug Deliv Trans Res</source>. (<year>2021</year>) <volume>11</volume>:<page-range>1340&#x02013;51</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s13346-021-00913-w</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baker</surname><given-names>RE</given-names></name><name><surname>Mahmud</surname><given-names>AS</given-names></name><name><surname>Miller</surname><given-names>IF</given-names></name><name><surname>Rajeev</surname><given-names>M</given-names></name><name><surname>Rasambainarivo</surname><given-names>F</given-names></name><name><surname>Rice</surname><given-names>BL</given-names></name><etal/></person-group>. <article-title>Infectious disease in an era of global change</article-title>. <source>Nat Rev Microbiol</source>. (<year>2022</year>) <volume>20</volume>:<fpage>193</fpage>&#x02013;<lpage>205</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41579-021-00639-z</pub-id>
<pub-id pub-id-type="pmid">34646006</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vetter</surname><given-names>V</given-names></name><name><surname>Denizer</surname><given-names>G</given-names></name><name><surname>Friedland</surname><given-names>LR</given-names></name><name><surname>Krishnan</surname><given-names>J</given-names></name><name><surname>Shapiro</surname><given-names>M</given-names></name></person-group>. <article-title>Understanding modern-day vaccines: what you need to know</article-title>. <source>Ann Med</source>. (<year>2018</year>) <volume>50</volume>:<page-range>110&#x02013;20</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/07853890.2017.1407035</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ali Khan</surname><given-names>A</given-names></name><name><surname>Munir</surname><given-names>M</given-names></name><name><surname>Miraj</surname><given-names>F</given-names></name><name><surname>Imran</surname><given-names>S</given-names></name><name><surname>Arif Siddiqi</surname><given-names>D</given-names></name><name><surname>Altaf</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Examining unsafe injection practices associated with auto-disable (Ad) syringes: A systematic review</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2021</year>) <volume>17</volume>:<page-range>3247&#x02013;58</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/21645515.2021.1911514</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Altaf</surname><given-names>A</given-names></name><name><surname>Qureshi</surname><given-names>H</given-names></name><name><surname>Orakzai</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name></person-group>. <article-title>Reuse of syringes for therapeutic injections in Pakistan: rethinking determinants</article-title>. <source>East Mediterr Health J</source>. (<year>2020</year>) <volume>26</volume>:<page-range>283&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.26719/emhj.19.028</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Mehl</surname><given-names>F</given-names></name><name><surname>Zeichner</surname><given-names>SL</given-names></name></person-group>. <article-title>Vaccine strategies to elicit mucosal immunity</article-title>. <source>Vaccines (Basel)</source>. (<year>2024</year>) <volume>12</volume>(<issue>2</issue>):<fpage>191</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/vaccines12020191</pub-id>
<pub-id pub-id-type="pmid">38400174</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Hufnagel</surname><given-names>S</given-names></name><name><surname>Cui</surname><given-names>Z</given-names></name></person-group>. <article-title>Intranasal vaccine: factors to consider in research and development</article-title>. <source>Int J Pharm</source>. (<year>2021</year>) <volume>609</volume>:<elocation-id>121180</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.121180</pub-id>
<pub-id pub-id-type="pmid">34637935</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mato</surname><given-names>YL</given-names></name></person-group>. <article-title>Nasal route for vaccine and drug delivery: features and current opportunities</article-title>. <source>Int J Pharm</source>. (<year>2019</year>) <volume>572</volume>:<fpage>118813</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.118813</pub-id>
<pub-id pub-id-type="pmid">31678521</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>H</given-names></name><name><surname>Kett</surname><given-names>V</given-names></name></person-group>. <article-title>Current prospects and future challenges for nasal vaccine delivery</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2017</year>) <volume>13</volume>:<fpage>34</fpage>&#x02013;<lpage>45</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/21645515.2016.1239668</pub-id>
<pub-id pub-id-type="pmid">27936348</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Fan</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Viral vector vaccine development and application during the covid-19 pandemic</article-title>. <source>Microorganisms</source>. (<year>2022</year>) <volume>10</volume>:<fpage>1450</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/microorganisms10071450</pub-id>
<pub-id pub-id-type="pmid">35889169</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diallo</surname><given-names>BK</given-names></name><name><surname>Ni Chasaide</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>TY</given-names></name><name><surname>Schmitt</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Weaver</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Intranasal covid-19 vaccine induces respiratory memory T cells and protects K18-hace mice against Sars-Cov-2 infection</article-title>. <source>NPJ Vaccines</source>. (<year>2023</year>) <volume>8</volume>:<fpage>68</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41541-023-00665-3</pub-id>
<pub-id pub-id-type="pmid">37179389</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kehagia</surname><given-names>E</given-names></name><name><surname>Papakyriakopoulou</surname><given-names>P</given-names></name><name><surname>Valsami</surname><given-names>G</given-names></name></person-group>. <article-title>Advances in intranasal vaccine delivery: A promising non-invasive route of immunization</article-title>. <source>Vaccine</source>. (<year>2023</year>) <volume>41</volume>:<page-range>3589&#x02013;603</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.vaccine.2023.05.011</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perego</surname><given-names>G</given-names></name><name><surname>Vigezzi</surname><given-names>GP</given-names></name><name><surname>Cocciolo</surname><given-names>G</given-names></name><name><surname>Chiappa</surname><given-names>F</given-names></name><name><surname>Salvati</surname><given-names>S</given-names></name><name><surname>Balzarini</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of spray intranasal live attenuated influenza vaccine: systematic review and meta-analysis</article-title>. <source>Vaccines (Basel)</source>. (<year>2021</year>) <volume>9</volume>(<issue>9</issue>):<fpage>998</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/vaccines9090998</pub-id>
<pub-id pub-id-type="pmid">34579235</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shakya</surname><given-names>AK</given-names></name><name><surname>Chowdhury</surname><given-names>MYE</given-names></name><name><surname>Tao</surname><given-names>W</given-names></name><name><surname>Gill</surname><given-names>HS</given-names></name></person-group>. <article-title>Mucosal vaccine delivery: current state and a pediatric perspective</article-title>. <source>J Control Release</source>. (<year>2016</year>) <volume>240</volume>:<fpage>394</fpage>&#x02013;<lpage>413</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jconrel.2016.02.014</pub-id>
<pub-id pub-id-type="pmid">26860287</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van der Ley</surname><given-names>PA</given-names></name><name><surname>Zariri</surname><given-names>A</given-names></name><name><surname>van Riet</surname><given-names>E</given-names></name><name><surname>Oosterhoff</surname><given-names>D</given-names></name><name><surname>Kruiswijk</surname><given-names>CP</given-names></name></person-group>. <article-title>An intranasal omv-based vaccine induces high mucosal and systemic protecting immunity against a Sars-Cov-2 infection</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>781280</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.781280</pub-id>
<pub-id pub-id-type="pmid">34987509</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Overton</surname><given-names>ET</given-names></name><name><surname>Goepfert</surname><given-names>PA</given-names></name><name><surname>Cunningham</surname><given-names>P</given-names></name><name><surname>Carter</surname><given-names>WA</given-names></name><name><surname>Horvath</surname><given-names>J</given-names></name><name><surname>Young</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Intranasal seasonal influenza vaccine and a tlr-3 agonist, rintatolimod, induced cross-reactive Iga antibody formation against Avian H5n1 and H7n9 influenza Ha in humans</article-title>. <source>Vaccine</source>. (<year>2014</year>) <volume>32</volume>:<page-range>5490&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.07.078</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gizurarson</surname><given-names>S</given-names></name></person-group>. <article-title>Anatomical and histological factors affecting intranasal drug and vaccine delivery</article-title>. <source>Curr Drug Deliv</source>. (<year>2012</year>) <volume>9</volume>:<page-range>566&#x02013;82</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2174/156720112803529828</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Teng</surname><given-names>Z</given-names></name><name><surname>Meng</surname><given-names>LY</given-names></name><name><surname>Yang</surname><given-names>JK</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>XG</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group>. <article-title>Bridging nanoplatform and vaccine delivery, a landscape of strategy to enhance nasal immunity</article-title>. <source>J Controlled Release</source>. (<year>2022</year>) <volume>351</volume>:<page-range>456&#x02013;75</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jconrel.2022.09.044</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sadeghi</surname><given-names>M</given-names></name><name><surname>Asadirad</surname><given-names>A</given-names></name><name><surname>Koushki</surname><given-names>K</given-names></name><name><surname>Shahbaz</surname><given-names>SK</given-names></name><name><surname>Dehnavi</surname><given-names>S</given-names></name></person-group>. <article-title>Recent advances in improving intranasal allergen-specific immunotherapy; focus on delivery systems and adjuvants</article-title>. <source>Int Immunopharmacol</source>. (<year>2022</year>) <volume>113</volume>(<issue>Pt A</issue>):<fpage>109327</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.intimp.2022.109327</pub-id>
<pub-id pub-id-type="pmid">36257257</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bernocchi</surname><given-names>B</given-names></name><name><surname>Carpentier</surname><given-names>R</given-names></name><name><surname>Betbeder</surname><given-names>D</given-names></name></person-group>. <article-title>Nasal nanovaccines</article-title>. <source>Int J Pharm</source>. (<year>2017</year>) <volume>530</volume>:<page-range>128&#x02013;38</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.07.012</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nian</surname><given-names>XX</given-names></name><name><surname>Zhang</surname><given-names>JY</given-names></name><name><surname>Huang</surname><given-names>SH</given-names></name><name><surname>Duan</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>XG</given-names></name><name><surname>Yang</surname><given-names>XM</given-names></name></person-group>. <article-title>Development of nasal vaccines and the associated challenges</article-title>. <source>Pharmaceutics</source>. (<year>2022</year>) <volume>14</volume>(<issue>10</issue>):<fpage>1983</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/pharmaceutics14101983</pub-id>
<pub-id pub-id-type="pmid">36297419</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Popescu</surname><given-names>R</given-names></name><name><surname>Ghica</surname><given-names>MV</given-names></name><name><surname>Dinu-Pirvu</surname><given-names>CE</given-names></name><name><surname>Anuta</surname><given-names>V</given-names></name><name><surname>Lupuliasa</surname><given-names>D</given-names></name><name><surname>Popa</surname><given-names>L</given-names></name></person-group>. <article-title>New opportunity to formulate intranasal vaccines and drug delivery systems based on chitosan</article-title>. <source>Int J Mol Sci</source>. (<year>2020</year>) <volume>21</volume>(<issue>14</issue>):<fpage>5016</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms21145016</pub-id>
<pub-id pub-id-type="pmid">32708704</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dmour</surname><given-names>I</given-names></name><name><surname>Islam</surname><given-names>N</given-names></name></person-group>. <article-title>Recent advances on chitosan as an adjuvant for vaccine delivery</article-title>. <source>Int J Biol Macromol</source>. (<year>2022</year>) <volume>200</volume>:<fpage>498</fpage>&#x02013;<lpage>519</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.12.129</pub-id>
<pub-id pub-id-type="pmid">34973993</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>WQ</given-names></name><name><surname>Meng</surname><given-names>QY</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>JB</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Chitosan derivatives and their application in biomedicine</article-title>. <source>Int J Mol Sci</source>. (<year>2020</year>) <volume>21</volume>(<issue>2</issue>):<fpage>487</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms21020487</pub-id>
<pub-id pub-id-type="pmid">31940963</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>YP</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>ZY</given-names></name><name><surname>Jiang</surname><given-names>HL</given-names></name><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>Preparation and immunological activity evaluation of an intranasal protein subunit vaccine against ancestral and mutant Sars-Cov-2 with Curdlan Sulfate/O-linked quaternized chitosan nanoparticles as carrier and adjuvant</article-title>. <source>Int J Biol Macromol</source>. (<year>2024</year>) <volume>276</volume>(<issue>Pt 1</issue>):<fpage>133733</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.133733</pub-id>
<pub-id pub-id-type="pmid">39002905</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Maharjan</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>KH</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Park</surname><given-names>IK</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name><etal/></person-group>. <article-title>Chitosan-based particulate systems for the delivery of mucosal vaccines against infectious diseases</article-title>. <source>Int J Biol Macromol</source>. (<year>2018</year>) <volume>110</volume>:<fpage>54</fpage>&#x02013;<lpage>64</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2017.10.101</pub-id>
<pub-id pub-id-type="pmid">29054527</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dyer</surname><given-names>AM</given-names></name><name><surname>Hinchcliffe</surname><given-names>M</given-names></name><name><surname>Watts</surname><given-names>P</given-names></name><name><surname>Castile</surname><given-names>J</given-names></name><name><surname>Jabbal-Gill</surname><given-names>I</given-names></name><name><surname>Nankervis</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles</article-title>. <source>Pharm Res</source>. (<year>2002</year>) <volume>19</volume>:<fpage>998</fpage>&#x02013;<lpage>1008</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1023/a:1016418523014</pub-id>
<pub-id pub-id-type="pmid">12180553</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>XM</given-names></name><name><surname>Gao</surname><given-names>TT</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Preparation and efficacy of a live newcastle disease virus vaccine encapsulated in chitosan nanoparticles</article-title>. <source>PloS One</source>. (<year>2012</year>) <volume>7</volume>:<fpage>e53314</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0053314</pub-id>
<pub-id pub-id-type="pmid">23285276</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shim</surname><given-names>S</given-names></name><name><surname>Yoo</surname><given-names>HS</given-names></name></person-group>. <article-title>The application of mucoadhesive chitosan nanoparticles in nasal drug delivery</article-title>. <source>Marine Drugs</source>. (<year>2020</year>) <volume>18</volume>(<issue>12</issue>):<fpage>605</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/md18120605</pub-id>
<pub-id pub-id-type="pmid">33260406</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>HL</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>YP</given-names></name><name><surname>Wang</surname><given-names>FS</given-names></name><name><surname>Jiang</surname><given-names>WJ</given-names></name></person-group>. <article-title>Preparation and characterization of curdlan-chitosan conjugate nanoparticles as mucosal adjuvants for intranasal influenza H1n1 subunit vaccine</article-title>. <source>Int J Biol Macromol</source>. (<year>2024</year>) <volume>266</volume>(<issue>Pt 2</issue>):<fpage>131289</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.131289</pub-id>
<pub-id pub-id-type="pmid">38570002</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pawar</surname><given-names>D</given-names></name><name><surname>Jaganathan</surname><given-names>KS</given-names></name></person-group>. <article-title>Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response</article-title>. <source>Drug Deliv</source>. (<year>2016</year>) <volume>23</volume>:<page-range>185&#x02013;94</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3109/10717544.2014.908427</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bento</surname><given-names>D</given-names></name><name><surname>Jesus</surname><given-names>S</given-names></name><name><surname>Lebre</surname><given-names>F</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>T</given-names></name><name><surname>Borges</surname><given-names>O</given-names></name></person-group>. <article-title>Chitosan plus compound 48/80: formulation and preliminary evaluation as a hepatitis B vaccine adjuvant</article-title>. <source>Pharmaceutics</source>. (<year>2019</year>) <volume>11</volume>(<issue>2</issue>):<fpage>72</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/pharmaceutics11020072</pub-id>
<pub-id pub-id-type="pmid">30744102</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rydell</surname><given-names>N</given-names></name><name><surname>Stertman</surname><given-names>L</given-names></name><name><surname>Sjoholm</surname><given-names>I</given-names></name></person-group>. <article-title>Starch microparticles as vaccine adjuvant</article-title>. <source>Expert Opin Drug Deliv</source>. (<year>2005</year>) <volume>2</volume>:<page-range>807&#x02013;28</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1517/17425247.2.5.807</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McDermott</surname><given-names>MR</given-names></name><name><surname>Heritage</surname><given-names>PL</given-names></name><name><surname>Bartzoka</surname><given-names>V</given-names></name><name><surname>Brook</surname><given-names>MA</given-names></name></person-group>. <article-title>Polymer-grafted starch microparticles for oral and nasal immunization</article-title>. <source>Immunol Cell Biol</source>. (<year>1998</year>) <volume>76</volume>:<page-range>256&#x02013;62</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1046/j.1440-1711.1998.00743.x</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Artursson</surname><given-names>P</given-names></name><name><surname>Edman</surname><given-names>P</given-names></name><name><surname>Ericsson</surname><given-names>JL</given-names></name></person-group>. <article-title>Macrophage stimulation with some structurally related polysaccharides</article-title>. <source>Scand J Immunol</source>. (<year>1987</year>) <volume>25</volume>:<page-range>245&#x02013;54</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1365-3083.1987.tb01070.x</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heritage</surname><given-names>PL</given-names></name><name><surname>Brook</surname><given-names>MA</given-names></name><name><surname>Underdown</surname><given-names>BJ</given-names></name><name><surname>McDermott</surname><given-names>MR</given-names></name></person-group>. <article-title>Intranasal immunization with polymer-grafted microparticles activates the nasal-associated lymphoid tissue and draining lymph nodes</article-title>. <source>Immunology</source>. (<year>1998</year>) <volume>93</volume>:<page-range>249&#x02013;56</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1046/j.1365-2567.1998.00420.x</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>RS</given-names></name><name><surname>Kaur</surname><given-names>N</given-names></name><name><surname>Hassan</surname><given-names>M</given-names></name><name><surname>Kennedy</surname><given-names>JF</given-names></name></person-group>. <article-title>Pullulan in biomedical research and development - a review</article-title>. <source>Int J Biol Macromol</source>. (<year>2021</year>) <volume>166</volume>:<fpage>694</fpage>&#x02013;<lpage>706</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.10.227</pub-id>
<pub-id pub-id-type="pmid">33137388</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yuki</surname><given-names>Y</given-names></name><name><surname>Nochi</surname><given-names>T</given-names></name><name><surname>Kong</surname><given-names>IG</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Sawada</surname><given-names>S</given-names></name><name><surname>Akiyoshi</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Nanogel-based antigen-delivery system for nasal vaccines</article-title>. <source>Biotechnol Genet Eng Rev</source>. (<year>2013</year>) <volume>29</volume>:<fpage>61</fpage>&#x02013;<lpage>72</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/02648725.2013.801226</pub-id>
<pub-id pub-id-type="pmid">24568253</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ayame</surname><given-names>H</given-names></name><name><surname>Morimoto</surname><given-names>N</given-names></name><name><surname>Akiyoshi</surname><given-names>K</given-names></name></person-group>. <article-title>Self-assembled cationic nanogels for intracellular protein delivery</article-title>. <source>Bioconjug Chem</source>. (<year>2008</year>) <volume>19</volume>:<page-range>882&#x02013;90</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1021/bc700422s</pub-id>
</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nochi</surname><given-names>T</given-names></name><name><surname>Yuki</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Sawada</surname><given-names>S</given-names></name><name><surname>Mejima</surname><given-names>M</given-names></name><name><surname>Kohda</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines</article-title>. <source>Nat Mater</source>. (<year>2010</year>) <volume>9</volume>:<page-range>572&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nmat2784</pub-id>
</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fukuyama</surname><given-names>Y</given-names></name><name><surname>Yuki</surname><given-names>Y</given-names></name><name><surname>Katakai</surname><given-names>Y</given-names></name><name><surname>Harada</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Nanogel-based pneumococcal surface protein a nasal vaccine induces microrna-associated th17 cell responses with neutralizing antibodies against streptococcus pneumoniae in macaques</article-title>. <source>Mucosal Immunol</source>. (<year>2015</year>) <volume>8</volume>:<page-range>1144&#x02013;53</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/mi.2015.5</pub-id>
</mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kong</surname><given-names>IG</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Yuki</surname><given-names>Y</given-names></name><name><surname>Nochi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Sawada</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Nanogel-based Pspa intranasal vaccine prevents invasive disease and nasal colonization by streptococcus pneumoniae</article-title>. <source>Infect Immun</source>. (<year>2013</year>) <volume>81</volume>:<page-range>1625&#x02013;34</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/IAI.00240-13</pub-id>
</mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yuki</surname><given-names>Y</given-names></name><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Sawada</surname><given-names>SI</given-names></name><name><surname>Nakahashi-Ouchida</surname><given-names>R</given-names></name><name><surname>Sugiura</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Characterization and specification of a trivalent protein-based pneumococcal vaccine formulation using an adjuvant-free nanogel nasal delivery system</article-title>. <source>Mol Pharm</source>. (<year>2021</year>) <volume>18</volume>:<page-range>1582&#x02013;92</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c01003</pub-id>
</mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fasquelle</surname><given-names>F</given-names></name><name><surname>Scuotto</surname><given-names>A</given-names></name><name><surname>Howsam</surname><given-names>M</given-names></name><name><surname>Betbeder</surname><given-names>D</given-names></name></person-group>. <article-title>Maltodextrin-nanoparticles as a delivery system for nasal vaccines: A review article</article-title>. <source>Pharmaceutics</source>. (<year>2024</year>) <volume>16</volume>(<issue>2</issue>):<fpage>247</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/pharmaceutics16020247</pub-id>
<pub-id pub-id-type="pmid">38399301</pub-id>
</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>von Hoegen</surname><given-names>P</given-names></name></person-group>. <article-title>Synthetic biomimetic supra molecular biovector (Smbv) particles for nasal vaccine delivery</article-title>. <source>Adv Drug Deliv Rev</source>. (<year>2001</year>) <volume>51</volume>:<page-range>113&#x02013;25</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s0169-409x(01)00175-2</pub-id>
</mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halperin</surname><given-names>SA</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Clarke</surname><given-names>K</given-names></name><name><surname>Treanor</surname><given-names>J</given-names></name><name><surname>Mabrouk</surname><given-names>T</given-names></name><name><surname>Germain</surname><given-names>M</given-names></name></person-group>. <article-title>Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults</article-title>. <source>Hum Vaccines</source>. (<year>2005</year>) <volume>1</volume>:<fpage>37</fpage>&#x02013;<lpage>42</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4161/hv.1.1.1553</pub-id>
</mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jallouli</surname><given-names>Y</given-names></name><name><surname>Paillard</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Sevin</surname><given-names>E</given-names></name><name><surname>Betbeder</surname><given-names>D</given-names></name></person-group>. <article-title>Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier <italic>in vitro</italic>
</article-title>. <source>Int J Pharm</source>. (<year>2007</year>) <volume>344</volume>:<page-range>103&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijpharm.2007.06.023</pub-id>
</mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bernocchi</surname><given-names>B</given-names></name><name><surname>Carpentier</surname><given-names>R</given-names></name><name><surname>Lantier</surname><given-names>I</given-names></name><name><surname>Ducournau</surname><given-names>C</given-names></name><name><surname>Dimier-Poisson</surname><given-names>I</given-names></name><name><surname>Betbeder</surname><given-names>D</given-names></name></person-group>. <article-title>Mechanisms allowing protein delivery in nasal mucosa using Npl nanoparticles</article-title>. <source>J Controlled Release</source>. (<year>2016</year>) <volume>232</volume>:<fpage>42</fpage>&#x02013;<lpage>50</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jconrel.2016.04.014</pub-id>
</mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>L&#x000ea;</surname><given-names>MQ</given-names></name><name><surname>Carpentier</surname><given-names>R</given-names></name><name><surname>Lantier</surname><given-names>I</given-names></name><name><surname>Ducournau</surname><given-names>C</given-names></name><name><surname>Fasquelle</surname><given-names>F</given-names></name><name><surname>Dimier-Poisson</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Protein delivery by porous cationic maltodextrin-based nanoparticles into nasal mucosal cells: comparison with cationic or anionic nanoparticles</article-title>. <source>Int J Pharmaceutics-X</source>. (<year>2019</year>) <volume>1</volume>:<fpage>100001</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijpx.2018.100001</pub-id>
</mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dimier-Poisson</surname><given-names>I</given-names></name><name><surname>Carpentier</surname><given-names>R</given-names></name><name><surname>N&#x02019;Guyen</surname><given-names>TT</given-names></name><name><surname>Dahmani</surname><given-names>F</given-names></name><name><surname>Ducournau</surname><given-names>C</given-names></name><name><surname>Betbeder</surname><given-names>D</given-names></name></person-group>. <article-title>Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic toxoplasma Gondii infection</article-title>. <source>Biomaterials</source>. (<year>2015</year>) <volume>50</volume>:<page-range>164&#x02013;75</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.biomaterials.2015.01.056</pub-id>
</mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Le</surname><given-names>MQ</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Bernasconi</surname><given-names>V</given-names></name><name><surname>Carpentier</surname><given-names>R</given-names></name><name><surname>Fasquelle</surname><given-names>F</given-names></name><name><surname>Lycke</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Prevention of influenza virus infection and transmission by intranasal administration of a porous maltodextrin nanoparticle-formulated vaccine</article-title>. <source>Int J Pharm</source>. (<year>2020</year>) <volume>582</volume>:<fpage>119348</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119348</pub-id>
<pub-id pub-id-type="pmid">32325240</pub-id>
</mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rebelatto</surname><given-names>MC</given-names></name><name><surname>Guimond</surname><given-names>P</given-names></name><name><surname>Bowersock</surname><given-names>TL</given-names></name><name><surname>HogenEsch</surname><given-names>H</given-names></name></person-group>. <article-title>Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles</article-title>. <source>Vet Immunol Immunopathol</source>. (<year>2001</year>) <volume>83</volume>:<fpage>93</fpage>&#x02013;<lpage>105</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s0165-2427(01)00370-1</pub-id>
<pub-id pub-id-type="pmid">11604164</pub-id>
</mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vasudevan</surname><given-names>UM</given-names></name><name><surname>Lee</surname><given-names>OK</given-names></name><name><surname>Lee</surname><given-names>EY</given-names></name></person-group>. <article-title>Alginate derived functional oligosaccharides: recent developments, barriers, and future outlooks</article-title>. <source>Carbohydr Polymers</source>. (<year>2021</year>) <volume>267</volume>:<fpage>118158</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.carbpol.2021.118158</pub-id>
</mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Cho</surname><given-names>CW</given-names></name><name><surname>Jeon</surname><given-names>JW</given-names></name><name><surname>Park</surname><given-names>JK</given-names></name><etal/></person-group>. <article-title>Nasal delivery of chitosan/alginate nanoparticle encapsulated bee (Apis mellifera) venom promotes antibody production and viral clearance during porcine reproductive and respiratory syndrome virus infection by modulating T cell related responses</article-title>. <source>Vet Immunol Immunopathol</source>. (<year>2018</year>) <volume>200</volume>:<fpage>40</fpage>&#x02013;<lpage>51</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.vetimm.2018.04.006</pub-id>
<pub-id pub-id-type="pmid">29776611</pub-id>
</mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jain</surname><given-names>RR</given-names></name><name><surname>Mehta</surname><given-names>MR</given-names></name><name><surname>Bannalikar</surname><given-names>AR</given-names></name><name><surname>Menon</surname><given-names>MD</given-names></name></person-group>. <article-title>Alginate microparticles loaded with lipopolysaccharide subunit antigen for mucosal vaccination against klebsiella pneumoniae</article-title>. <source>Biologicals</source>. (<year>2015</year>) <volume>43</volume>:<fpage>195</fpage>&#x02013;<lpage>201</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.biologicals.2015.02.001</pub-id>
<pub-id pub-id-type="pmid">25737397</pub-id>
</mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>KS</given-names></name></person-group>. <article-title>Effect of alginate on innate immune activation of macrophages</article-title>. <source>J Biomed Mater Res Part A</source>. (<year>2009</year>) <volume>90A</volume>:<page-range>411&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/jbm.a.32096</pub-id>
</mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mosafer</surname><given-names>J</given-names></name><name><surname>Sabbaghi</surname><given-names>AH</given-names></name><name><surname>Badiee</surname><given-names>A</given-names></name><name><surname>Dehghan</surname><given-names>S</given-names></name><name><surname>Tafaghodi</surname><given-names>M</given-names></name></person-group>. <article-title>Preparation, characterization and <italic>in vivo</italic> evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with Pr8 influenza virus for nasal immunization</article-title>. <source>Asian J Pharm Sci</source>. (<year>2019</year>) <volume>14</volume>:<page-range>216&#x02013;21</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ajps.2018.04.005</pub-id>
</mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Yoshizaki</surname><given-names>Y</given-names></name><name><surname>Horii</surname><given-names>K</given-names></name><name><surname>Murase</surname><given-names>N</given-names></name><name><surname>Kuzuya</surname><given-names>A</given-names></name><name><surname>Ohya</surname><given-names>Y</given-names></name></person-group>. <article-title>Preparation of hyaluronic acid-coated polymeric micelles for nasal vaccine delivery</article-title>. <source>Biomater Sci</source>. (<year>2022</year>) <volume>10</volume>:<page-range>1920&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1039/d1bm01985f</pub-id>
</mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Parmar</surname><given-names>A</given-names></name><name><surname>Kori</surname><given-names>S</given-names></name><name><surname>Sandhir</surname><given-names>R</given-names></name></person-group>. <article-title>Plga-based nanoparticles: A new paradigm in biomedical applications</article-title>. <source>Trac Trends Anal Chem</source>. (<year>2016</year>) <volume>80</volume>:<fpage>30</fpage>&#x02013;<lpage>40</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.trac.2015.06.014</pub-id>
</mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alsaab</surname><given-names>HO</given-names></name><name><surname>Alharbi</surname><given-names>FD</given-names></name><name><surname>Alhibs</surname><given-names>AS</given-names></name><name><surname>Alanazi</surname><given-names>NB</given-names></name><name><surname>Alshehri</surname><given-names>BY</given-names></name><name><surname>Saleh</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Plga-based nanomedicine: history of advancement and development in clinical applications of multiple diseases</article-title>. <source>Pharmaceutics</source>. (<year>2022</year>) <volume>14</volume>(<issue>12</issue>):<fpage>2728</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/pharmaceutics14122728</pub-id>
<pub-id pub-id-type="pmid">36559223</pub-id>
</mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kabiri</surname><given-names>M</given-names></name><name><surname>Sankian</surname><given-names>M</given-names></name><name><surname>Sadri</surname><given-names>K</given-names></name><name><surname>Tafaghodi</surname><given-names>M</given-names></name></person-group>. <article-title>Robust mucosal and systemic responses against Htlv-1 by delivery of multiepitope vaccine in Plga nanoparticles</article-title>. <source>Eur J Pharm Biopharm</source>. (<year>2018</year>) <volume>133</volume>:<page-range>321&#x02013;30</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ejpb.2018.11.003</pub-id>
</mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shao</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name></person-group>. <article-title>Recent advances in Plga micro/nanoparticle delivery systems as novel therapeutic approach for drug-resistant tuberculosis</article-title>. <source>Front Bioeng Biotechnol</source>. (<year>2022</year>) <volume>10</volume>:<elocation-id>941077</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fbioe.2022.941077</pub-id>
<pub-id pub-id-type="pmid">35935487</pub-id>
</mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>B&#x000fc;y&#x000fc;kbayraktar</surname><given-names>HK</given-names></name><name><surname>Araici</surname><given-names>PP</given-names></name><name><surname>Ihlamur</surname><given-names>M</given-names></name><name><surname>G&#x000f6;kkaya</surname><given-names>D</given-names></name><name><surname>Karahan</surname><given-names>M</given-names></name><name><surname>Abamor</surname><given-names>ES</given-names></name><etal/></person-group>. <article-title>Effect of polycation coating on the long-term pulsatile release of antigenic Esat-61&#x02013;20 peptide from Plga nanoparticles</article-title>. <source>Colloids Surf B Biointerf</source>. (<year>2023</year>) <volume>228</volume>:<fpage>113421</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.colsurfb.2023.113421</pub-id>
</mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jeong</surname><given-names>EH</given-names></name><name><surname>Jung</surname><given-names>G</given-names></name><name><surname>Hong</surname><given-names>CA</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name></person-group>. <article-title>Gold nanoparticle (Aunp)-based drug delivery and molecular imaging for biomedical applications</article-title>. <source>Arch Pharmacal Res</source>. (<year>2014</year>) <volume>37</volume>:<page-range>53&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s12272-013-0273-5</pub-id>
</mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Connor</surname><given-names>DM</given-names></name><name><surname>Broome</surname><given-names>AM</given-names></name></person-group>. <article-title>Gold nanoparticles for the delivery of cancer therapeutics</article-title>. <source>Adv Cancer Res</source>. (<year>2018</year>) <volume>139</volume>:<page-range>163&#x02013;84</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/bs.acr.2018.05.001</pub-id>
</mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nicol</surname><given-names>JR</given-names></name><name><surname>Dixon</surname><given-names>D</given-names></name><name><surname>Coulter</surname><given-names>JA</given-names></name></person-group>. <article-title>Gold nanoparticle surface functionalization: A necessary requirement in the development of novel nanotherapeutics</article-title>. <source>Nanomedicine</source>. (<year>2015</year>) <volume>10</volume>:<page-range>1315&#x02013;26</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2217/nnm.14.219</pub-id>
</mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amina</surname><given-names>SJ</given-names></name><name><surname>Guo</surname><given-names>B</given-names></name></person-group>. <article-title>A review on the synthesis and functionalization of gold nanoparticles as a drug delivery vehicle</article-title>. <source>Int J Nanomed</source>. (<year>2020</year>) <volume>15</volume>:<page-range>9823&#x02013;57</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2147/ijn.S279094</pub-id>
</mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>HJ</given-names></name><name><surname>Li</surname><given-names>YT</given-names></name><name><surname>Zhao</surname><given-names>BB</given-names></name><name><surname>Zheng</surname><given-names>CX</given-names></name><name><surname>Niu</surname><given-names>MY</given-names></name><name><surname>Song</surname><given-names>QL</given-names></name><etal/></person-group>. <article-title>Orchestrating antigen delivery and presentation efficiency in lymph node by nanoparticle shape for immune response</article-title>. <source>Acta Pharm Sin B</source>. (<year>2023</year>) <volume>13</volume>:<page-range>3892&#x02013;905</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.apsb.2023.02.003</pub-id>
</mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumar</surname><given-names>US</given-names></name><name><surname>Afjei</surname><given-names>R</given-names></name><name><surname>Ferrara</surname><given-names>K</given-names></name><name><surname>Massoud</surname><given-names>TF</given-names></name><name><surname>Paulmurugan</surname><given-names>R</given-names></name></person-group>. <article-title>Gold-nanostar-chitosan-mediated delivery of Sars-Cov-2 DNA vaccine for respiratory mucosal immunization: development and proof-of-principle</article-title>. <source>ACS Nano</source>. (<year>2021</year>) <volume>15</volume>:<page-range>17582&#x02013;601</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1021/acsnano.1c05002</pub-id>
</mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tapia</surname><given-names>D</given-names></name><name><surname>Sanchez-Villamil</surname><given-names>JI</given-names></name><name><surname>Torres</surname><given-names>AG</given-names></name></person-group>. <article-title>Multicomponent gold nano-glycoconjugate as a highly immunogenic and protective platform against burkholderia mallei</article-title>. <source>NPJ Vaccines</source>. (<year>2020</year>) <volume>5</volume>:<fpage>82</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41541-020-00229-9</pub-id>
<pub-id pub-id-type="pmid">32963813</pub-id>
</mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yin</surname><given-names>YL</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>HL</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name></person-group>. <article-title>Nanogel: A versatile nano-delivery system for biomedical applications</article-title>. <source>Pharmaceutics</source>. (<year>2020</year>) <volume>12</volume>:<fpage>290</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/pharmaceutics12030290</pub-id>
<pub-id pub-id-type="pmid">32210184</pub-id>
</mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soni</surname><given-names>KS</given-names></name><name><surname>Desale</surname><given-names>SS</given-names></name><name><surname>Bronich</surname><given-names>TK</given-names></name></person-group>. <article-title>Nanogels: an overview of properties, biomedical applications and obstacles to clinical translation</article-title>. <source>J Controlled Release</source>. (<year>2016</year>) <volume>240</volume>:<page-range>109&#x02013;26</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jconrel.2015.11.009</pub-id>
</mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>YL</given-names></name><name><surname>Maciel</surname><given-names>D</given-names></name><name><surname>Rodrigues</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>XY</given-names></name><name><surname>Tom&#x000e1;s</surname><given-names>H</given-names></name></person-group>. <article-title>Biodegradable polymer nanogels for drug/nucleic acid delivery</article-title>. <source>Chem Rev</source>. (<year>2015</year>) <volume>115</volume>:<page-range>8564&#x02013;608</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1021/cr500131f</pub-id>
</mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sahiner</surname><given-names>N</given-names></name><name><surname>Godbey</surname><given-names>WT</given-names></name><name><surname>McPherson</surname><given-names>GL</given-names></name><name><surname>John</surname><given-names>VT</given-names></name></person-group>. <article-title>Microgel, nanogel and hydrogel-hydrogel semi-Ipn composites for biomedical applications: synthesis and characterization</article-title>. <source>Colloid Polymer Sci</source>. (<year>2006</year>) <volume>284</volume>:<page-range>1121&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00396-006-1489-4</pub-id>
</mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kabanov</surname><given-names>AV</given-names></name><name><surname>Vinogradov</surname><given-names>SV</given-names></name></person-group>. <article-title>Nanogels as pharmaceutical carriers: finite networks of infinite capabilities</article-title>. <source>Angewandte Chemie International Edition</source>. (<year>2009</year>) <volume>48</volume>:<page-range>5418&#x02013;29</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/anie.200900441</pub-id>
</mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>JZ</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>SL</given-names></name><etal/></person-group>. <article-title>Intranasal delivery of endothelial cell-derived extracellular vesicles with supramolecular gel attenuates myocardial ischemia-reperfusion injury</article-title>. <source>Int J Nanomed</source>. (<year>2023</year>) <volume>18</volume>:<page-range>5495&#x02013;510</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2147/ijn.S420301</pub-id>
</mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marasini</surname><given-names>N</given-names></name><name><surname>Skwarczynski</surname><given-names>M</given-names></name><name><surname>Toth</surname><given-names>I</given-names></name></person-group>. <article-title>Intranasal delivery of nanoparticle-based vaccines</article-title>. <source>Ther Deliv</source>. (<year>2017</year>) <volume>8</volume>:<page-range>151&#x02013;67</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4155/tde-2016-0068</pub-id>
</mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marasini</surname><given-names>N</given-names></name><name><surname>Khalil</surname><given-names>ZG</given-names></name><name><surname>Giddam</surname><given-names>AK</given-names></name><name><surname>Ghaffar</surname><given-names>KA</given-names></name><name><surname>Hussein</surname><given-names>WM</given-names></name><name><surname>Capon</surname><given-names>RJ</given-names></name><etal/></person-group>. <article-title>Lipid core peptide/poly(Lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against group a streptococcus</article-title>. <source>Int J Pharm</source>. (<year>2016</year>) <volume>513</volume>:<page-range>410&#x02013;20</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.09.057</pub-id>
</mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zaman</surname><given-names>M</given-names></name><name><surname>Chandrudu</surname><given-names>S</given-names></name><name><surname>Giddam</surname><given-names>AK</given-names></name><name><surname>Reiman</surname><given-names>J</given-names></name><name><surname>Skwarczynski</surname><given-names>M</given-names></name><name><surname>McPhun</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Group a streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity</article-title>. <source>Nanomedicine</source>. (<year>2014</year>) <volume>9</volume>:<page-range>2613&#x02013;24</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2217/nnm.14.190</pub-id>
</mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fan</surname><given-names>YC</given-names></name><name><surname>Marioli</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name></person-group>. <article-title>Analytical characterization of liposomes and other lipid nanoparticles for drug delivery</article-title>. <source>J Pharm Biomed Anal</source>. (<year>2021</year>) <volume>192</volume>:<fpage>113642</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jpba.2020.113642</pub-id>
<pub-id pub-id-type="pmid">33011580</pub-id>
</mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amin</surname><given-names>M</given-names></name><name><surname>Seynhaeve</surname><given-names>ALB</given-names></name><name><surname>Sharifi</surname><given-names>M</given-names></name><name><surname>Falahati</surname><given-names>M</given-names></name><name><surname>ten Hagen</surname><given-names>TLM</given-names></name></person-group>. <article-title>Liposomal drug delivery systems for cancer therapy: the Rotterdam experience</article-title>. <source>Pharmaceutics</source>. (<year>2022</year>) <volume>14</volume>:<fpage>2165</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/pharmaceutics14102165</pub-id>
<pub-id pub-id-type="pmid">36297598</pub-id>
</mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nikolova</surname><given-names>MP</given-names></name><name><surname>Kumar</surname><given-names>EM</given-names></name><name><surname>Chavali</surname><given-names>MS</given-names></name></person-group>. <article-title>Updates on responsive drug delivery based on liposome vehicles for cancer treatment</article-title>. <source>Pharmaceutics</source>. (<year>2022</year>) <volume>14</volume>(<issue>10</issue>):<fpage>2195</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/pharmaceutics14102195</pub-id>
<pub-id pub-id-type="pmid">36297630</pub-id>
</mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>SQ</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Lovell</surname><given-names>JF</given-names></name></person-group>. <article-title>Vaccine approaches for antigen capture by liposomes</article-title>. <source>Expert Rev Vaccines</source>. (<year>2023</year>) <volume>22</volume>:<page-range>1022&#x02013;40</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/14760584.2023.2274479</pub-id>
</mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duong</surname><given-names>VA</given-names></name><name><surname>Nguyen</surname><given-names>TTL</given-names></name><name><surname>Maeng</surname><given-names>HJ</given-names></name></person-group>. <article-title>Recent advances in intranasal liposomes for drug, gene, and vaccine delivery</article-title>. <source>Pharmaceutics</source>. (<year>2023</year>) <volume>15</volume>(<issue>1</issue>):<fpage>207</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/pharmaceutics15010207</pub-id>
<pub-id pub-id-type="pmid">36678838</pub-id>
</mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tada</surname><given-names>R</given-names></name><name><surname>Hidaka</surname><given-names>A</given-names></name><name><surname>Iwase</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Yamakita</surname><given-names>Y</given-names></name><name><surname>Iwata</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Intranasal immunization with dotap cationic liposomes combined with dc-cholesterol induces potent antigen-specific mucosal and systemic immune responses in mice</article-title>. <source>PloS One</source>. (<year>2015</year>) <volume>10</volume>(<issue>10</issue>):<elocation-id>e0139785</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0139785</pub-id>
<pub-id pub-id-type="pmid">26440657</pub-id>
</mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sia</surname><given-names>ZR</given-names></name><name><surname>Chiem</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>WC</given-names></name><name><surname>Seffouh</surname><given-names>A</given-names></name><name><surname>Dereshgi</surname><given-names>AT</given-names></name><name><surname>Hogan</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Respiratory vaccination with hemagglutinin nanoliposomes protects mice from homologous and heterologous strains of influenza virus</article-title>. <source>J Virol</source>. (<year>2022</year>) <volume>96</volume>(<issue>19</issue>):<elocation-id>e0100622</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/jvi.01006-22</pub-id>
<pub-id pub-id-type="pmid">36106872</pub-id>
</mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>B</given-names></name><name><surname>Biswas</surname><given-names>S</given-names></name></person-group>. <article-title>Polymeric micelles in cancer therapy: state of the art</article-title>. <source>J Controlled Release</source>. (<year>2021</year>) <volume>332</volume>:<page-range>127&#x02013;47</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jconrel.2021.02.016</pub-id>
</mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chakravarty</surname><given-names>M</given-names></name><name><surname>Vora</surname><given-names>A</given-names></name></person-group>. <article-title>Nanotechnology-based antiviral therapeutics</article-title>. <source>Drug Deliv Trans Res</source>. (<year>2021</year>) <volume>11</volume>:<page-range>748&#x02013;87</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s13346-020-00818-0</pub-id>
</mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perumal</surname><given-names>S</given-names></name><name><surname>Atchudan</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name></person-group>. <article-title>A review of polymeric micelles and their applications</article-title>. <source>Polymers</source>. (<year>2022</year>) <volume>14</volume>(<issue>12</issue>):<fpage>2510</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/polym14122510</pub-id>
<pub-id pub-id-type="pmid">35746086</pub-id>
</mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shang</surname><given-names>S</given-names></name><name><surname>Kats</surname><given-names>D</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Morgun</surname><given-names>E</given-names></name><name><surname>Velluto</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Induction of mycobacterium tuberculosis lipid-specific T cell responses by pulmonary delivery of mycolic acid-loaded polymeric micellar nanocarriers</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<elocation-id>2709</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2018.02709</pub-id>
<pub-id pub-id-type="pmid">30538700</pub-id>
</mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Krummenacher</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Urgency and necessity of Epstein-Barr virus prophylactic vaccines</article-title>. <source>NPJ Vaccines</source>. (<year>2022</year>) <volume>7</volume>:<fpage>159</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41541-022-00587-6</pub-id>
<pub-id pub-id-type="pmid">36494369</pub-id>
</mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hadj Hassine</surname><given-names>I</given-names></name><name><surname>Ben M&#x02019;hadheb</surname><given-names>M</given-names></name><name><surname>Almalki</surname><given-names>MA</given-names></name><name><surname>Gharbi</surname><given-names>J</given-names></name></person-group>. <article-title>Virus-like particles as powerful vaccination strategy against human viruses</article-title>. <source>Rev Med Virol</source>. (<year>2024</year>) <volume>34</volume>:<fpage>e2498</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/rmv.2498</pub-id>
<pub-id pub-id-type="pmid">38116958</pub-id>
</mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nooraei</surname><given-names>S</given-names></name><name><surname>Bahrulolum</surname><given-names>H</given-names></name><name><surname>Hoseini</surname><given-names>ZS</given-names></name><name><surname>Katalani</surname><given-names>C</given-names></name><name><surname>Hajizade</surname><given-names>A</given-names></name><name><surname>Easton</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers</article-title>. <source>J Nanobiotechnol</source>. (<year>2021</year>) <volume>19</volume>:<fpage>59</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12951-021-00806-7</pub-id>
</mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steinmetz</surname><given-names>NF</given-names></name></person-group>. <article-title>Viral nanoparticles as platforms for next-generation therapeutics and imaging devices</article-title>. <source>Nanomedicine</source>. (<year>2010</year>) <volume>6</volume>:<page-range>634&#x02013;41</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.nano.2010.04.005</pub-id>
</mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qian</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Recent progress on the versatility of virus-like particles</article-title>. <source>Vaccines (Basel)</source>. (<year>2020</year>) <volume>8</volume>(<issue>1</issue>):<fpage>139</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/vaccines8010139</pub-id>
<pub-id pub-id-type="pmid">32244935</pub-id>
</mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsakiri</surname><given-names>M</given-names></name><name><surname>Naziris</surname><given-names>N</given-names></name><name><surname>Demetzos</surname><given-names>C</given-names></name></person-group>. <article-title>Innovative vaccine platforms against infectious diseases: under the scope of the covid-19 pandemic</article-title>. <source>Int J Pharm</source>. (<year>2021</year>) <volume>610</volume>:<elocation-id>121212</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.121212</pub-id>
<pub-id pub-id-type="pmid">34687816</pub-id>
</mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bai</surname><given-names>Z</given-names></name><name><surname>Wan</surname><given-names>D</given-names></name><name><surname>Lan</surname><given-names>T</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Nanoplatform based intranasal vaccines: current progress and clinical challenges</article-title>. <source>ACS Nano</source>. (<year>2024</year>) <volume>18</volume>:<page-range>24650&#x02013;81</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1021/acsnano.3c10797</pub-id>
</mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rothen</surname><given-names>DA</given-names></name><name><surname>Krenger</surname><given-names>PS</given-names></name><name><surname>Nonic</surname><given-names>A</given-names></name><name><surname>Balke</surname><given-names>I</given-names></name><name><surname>Vogt</surname><given-names>AS</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against Sars-Cov-2 and variants of concern</article-title>. <source>Allergy</source>. (<year>2022</year>) <volume>77</volume>:<page-range>2446&#x02013;58</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/all.15311</pub-id>
</mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>Y</given-names></name><name><surname>Meher</surname><given-names>JG</given-names></name><name><surname>Raval</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>FA</given-names></name><name><surname>Chaurasia</surname><given-names>M</given-names></name><name><surname>Jain</surname><given-names>NK</given-names></name><etal/></person-group>. <article-title>Nanoemulsion: concepts, development and applications in drug delivery</article-title>. <source>J Controlled Release</source>. (<year>2017</year>) <volume>252</volume>:<fpage>28</fpage>&#x02013;<lpage>49</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jconrel.2017.03.008</pub-id>
</mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>PT</given-names></name><name><surname>Wang</surname><given-names>SH</given-names></name><name><surname>Ciotti</surname><given-names>S</given-names></name><name><surname>Makidon</surname><given-names>PE</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Fan</surname><given-names>YY</given-names></name><etal/></person-group>. <article-title>Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity</article-title>. <source>Mol Pharm</source>. (<year>2014</year>) <volume>11</volume>:<page-range>531&#x02013;44</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1021/mp4005029</pub-id>
</mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stephenson</surname><given-names>I</given-names></name><name><surname>Zambon</surname><given-names>MC</given-names></name><name><surname>Rudin</surname><given-names>A</given-names></name><name><surname>Colegate</surname><given-names>A</given-names></name><name><surname>Podda</surname><given-names>A</given-names></name><name><surname>Bugarini</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers</article-title>. <source>J Virol</source>. (<year>2006</year>) <volume>80</volume>:<page-range>4962&#x02013;70</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.80.10.4962-4970.2006</pub-id>
</mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stanberry</surname><given-names>LR</given-names></name><name><surname>Simon</surname><given-names>JK</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Robinson</surname><given-names>PL</given-names></name><name><surname>Morry</surname><given-names>J</given-names></name><name><surname>Flack</surname><given-names>MR</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805ec combined with approved seasonal influenza antigens</article-title>. <source>Vaccine</source>. (<year>2012</year>) <volume>30</volume>:<page-range>307&#x02013;16</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.10.094</pub-id>
</mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Makidon</surname><given-names>PE</given-names></name><name><surname>Bielinska</surname><given-names>AU</given-names></name><name><surname>Nigavekar</surname><given-names>SS</given-names></name><name><surname>Janczak</surname><given-names>KW</given-names></name><name><surname>Knowlton</surname><given-names>J</given-names></name><name><surname>Scott</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine</article-title>. <source>PloS One</source>. (<year>2008</year>) <volume>3</volume>(<issue>8</issue>):<elocation-id>e2954</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0002954</pub-id>
<pub-id pub-id-type="pmid">18698426</pub-id>
</mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>HW</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>You</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Epitope-loaded nanoemulsion delivery system with ability of extending antigen release elicits potent Th1 response for intranasal vaccine against helicobacter pylori</article-title>. <source>J Nanobiotechnol</source>. (<year>2019</year>) <volume>17</volume>:<elocation-id>6</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12951-019-0441-y</pub-id>
</mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jangra</surname><given-names>S</given-names></name><name><surname>Landers</surname><given-names>JJ</given-names></name><name><surname>Rathnasinghe</surname><given-names>R</given-names></name><name><surname>O&#x02019;Konek</surname><given-names>JJ</given-names></name><name><surname>Janczak</surname><given-names>KW</given-names></name><name><surname>Cascalho</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A combination adjuvant for the induction of potent antiviral immune responses for a recombinant Sars-Cov-2 protein vaccine</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>729189</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.729189</pub-id>
<pub-id pub-id-type="pmid">34603303</pub-id>
</mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Sheng</surname><given-names>YA</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>ZJ</given-names></name><name><surname>Yang</surname><given-names>YL</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Oil-in-ionic liquid nanoemulsion-based intranasal delivery system for influenza split-virus vaccine</article-title>. <source>J Controlled Release</source>. (<year>2022</year>) <volume>346</volume>:<page-range>380&#x02013;91</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jconrel.2022.04.036</pub-id>
</mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hill</surname><given-names>C</given-names></name><name><surname>Guarner</surname><given-names>F</given-names></name><name><surname>Reid</surname><given-names>G</given-names></name><name><surname>Gibson</surname><given-names>GR</given-names></name><name><surname>Merenstein</surname><given-names>DJ</given-names></name><name><surname>Pot</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. (<year>2014</year>) <volume>11</volume>:<page-range>506&#x02013;14</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nrgastro.2014.66</pub-id>
</mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wyszynska</surname><given-names>A</given-names></name><name><surname>Kobierecka</surname><given-names>P</given-names></name><name><surname>Bardowski</surname><given-names>J</given-names></name><name><surname>Jagusztyn-Krynicka</surname><given-names>EK</given-names></name></person-group>. <article-title>Lactic acid bacteria-20 years exploring their potential as live vectors for mucosal vaccination</article-title>. <source>Appl Microbiol Biotechnol</source>. (<year>2015</year>) <volume>99</volume>:<page-range>2967&#x02013;77</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00253-015-6498-0</pub-id>
</mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosales-Mendoza</surname><given-names>S</given-names></name><name><surname>Angulo</surname><given-names>C</given-names></name><name><surname>Meza</surname><given-names>B</given-names></name></person-group>. <article-title>Food-grade organisms as vaccine biofactories and oral delivery vehicles</article-title>. <source>Trends Biotechnol</source>. (<year>2016</year>) <volume>34</volume>:<page-range>124&#x02013;36</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.tibtech.2015.11.007</pub-id>
</mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saggese</surname><given-names>A</given-names></name><name><surname>Baccigalupi</surname><given-names>L</given-names></name><name><surname>Donadio</surname><given-names>G</given-names></name><name><surname>Ricca</surname><given-names>E</given-names></name><name><surname>Isticato</surname><given-names>R</given-names></name></person-group>. <article-title>The bacterial spore as a mucosal vaccine delivery system</article-title>. <source>Int J Mol Sci</source>. (<year>2023</year>) <volume>24</volume>(<issue>13</issue>):<fpage>10880</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms241310880</pub-id>
<pub-id pub-id-type="pmid">37446054</pub-id>
</mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>JM</given-names></name><name><surname>Hong</surname><given-names>HA</given-names></name><name><surname>Hoang</surname><given-names>VT</given-names></name><name><surname>Hoang</surname><given-names>TH</given-names></name><name><surname>Brisson</surname><given-names>A</given-names></name><name><surname>Cutting</surname><given-names>SM</given-names></name></person-group>. <article-title>Mucosal delivery of antigens using adsorption to bacterial spores</article-title>. <source>Vaccine</source>. (<year>2010</year>) <volume>28</volume>:<page-range>1021&#x02013;30</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.10.127</pub-id>
</mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Souza</surname><given-names>RD</given-names></name><name><surname>Batista</surname><given-names>MT</given-names></name><name><surname>Luiz</surname><given-names>WB</given-names></name><name><surname>Cavalcante</surname><given-names>RC</given-names></name><name><surname>Amorim</surname><given-names>JH</given-names></name><name><surname>Bizerra</surname><given-names>RS</given-names></name><etal/></person-group>. <article-title>Bacillus subtilis spores as vaccine adjuvants: further insights into the mechanisms of action</article-title>. <source>PloS One</source>. (<year>2014</year>) <volume>9</volume>:<fpage>e87454</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0087454</pub-id>
<pub-id pub-id-type="pmid">24475289</pub-id>
</mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McKenney</surname><given-names>PT</given-names></name><name><surname>Driks</surname><given-names>A</given-names></name><name><surname>Eichenberger</surname><given-names>P</given-names></name></person-group>. <article-title>The bacillus subtilis endospore: assembly and functions of the multilayered coat</article-title>. <source>Nat Rev Microbiol</source>. (<year>2013</year>) <volume>11</volume>:<fpage>33</fpage>&#x02013;<lpage>44</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nrmicro2921</pub-id>
<pub-id pub-id-type="pmid">23202530</pub-id>
</mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Isticato</surname><given-names>R</given-names></name><name><surname>Sirec</surname><given-names>T</given-names></name><name><surname>Treppiccione</surname><given-names>L</given-names></name><name><surname>Maurano</surname><given-names>F</given-names></name><name><surname>De Felice</surname><given-names>M</given-names></name><name><surname>Rossi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Non-recombinant display of the B subunit of the heat labile toxin of escherichia coli on wild type and mutant spores of bacillus subtilis</article-title>. <source>Microb Cell Fact</source>. (<year>2013</year>) <volume>12</volume>:<elocation-id>98</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/1475-2859-12-98</pub-id>
<pub-id pub-id-type="pmid">24168229</pub-id>
</mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Hong</surname><given-names>HA</given-names></name><name><surname>Huang</surname><given-names>JM</given-names></name><name><surname>Colenutt</surname><given-names>C</given-names></name><name><surname>Khang</surname><given-names>DD</given-names></name><name><surname>Nguyen</surname><given-names>TV</given-names></name><etal/></person-group>. <article-title>Killed bacillus subtilis spores as a mucosal adjuvant for an H5n1 vaccine</article-title>. <source>Vaccine</source>. (<year>2012</year>) <volume>30</volume>:<page-range>3266&#x02013;77</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.03.016</pub-id>
</mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Almeida</surname><given-names>MEM</given-names></name><name><surname>Alves</surname><given-names>KCS</given-names></name><name><surname>de Vasconcelos</surname><given-names>MGS</given-names></name><name><surname>Pinto</surname><given-names>TS</given-names></name><name><surname>Gloria</surname><given-names>JC</given-names></name><name><surname>Chaves</surname><given-names>YO</given-names></name><etal/></person-group>. <article-title>Bacillus subtilis spores as delivery system for nasal plasmodium falciparum circumsporozoite surface protein immunization in a murine model</article-title>. <source>Sci Rep</source>. (<year>2022</year>) <volume>12</volume>:<fpage>1531</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41598-022-05344-2</pub-id>
<pub-id pub-id-type="pmid">35087102</pub-id>
</mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maia</surname><given-names>AR</given-names></name><name><surname>Reyes-Ramirez</surname><given-names>R</given-names></name><name><surname>Pizarro-Guajardo</surname><given-names>M</given-names></name><name><surname>Saggese</surname><given-names>A</given-names></name><name><surname>Castro-Cordova</surname><given-names>P</given-names></name><name><surname>Isticato</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Induction of a specific humoral immune response by nasal delivery of Bcla2(Ctd) of clostridioides difficile</article-title>. <source>Int J Mol Sci</source>. (<year>2020</year>) <volume>21</volume>(<issue>4</issue>):<fpage>1277</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms21041277</pub-id>
<pub-id pub-id-type="pmid">32074955</pub-id>
</mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maia</surname><given-names>AR</given-names></name><name><surname>Reyes-Ramirez</surname><given-names>R</given-names></name><name><surname>Pizarro-Guajardo</surname><given-names>M</given-names></name><name><surname>Saggese</surname><given-names>A</given-names></name><name><surname>Ricca</surname><given-names>E</given-names></name><name><surname>Baccigalupi</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Nasal immunization with the C-terminal domain of bcla3 induced specific igg production and attenuated disease symptoms in mice infected with clostridioides difficile spores</article-title>. <source>Int J Mol Sci</source>. (<year>2020</year>) <volume>21</volume>(<issue>18</issue>):<fpage>6696</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms21186696</pub-id>
<pub-id pub-id-type="pmid">32933117</pub-id>
</mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Santos</surname><given-names>FDS</given-names></name><name><surname>Mazzoli</surname><given-names>A</given-names></name><name><surname>Maia</surname><given-names>AR</given-names></name><name><surname>Saggese</surname><given-names>A</given-names></name><name><surname>Isticato</surname><given-names>R</given-names></name><name><surname>Leite</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>A probiotic treatment increases the immune response induced by the nasal delivery of spore-adsorbed ttfc</article-title>. <source>Microb Cell Factories</source>. (<year>2020</year>) <volume>19</volume>(<issue>1</issue>):<fpage>42</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12934-020-01308-1</pub-id>
</mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sarate</surname><given-names>PJ</given-names></name><name><surname>Heinl</surname><given-names>S</given-names></name><name><surname>Poiret</surname><given-names>S</given-names></name><name><surname>Drinic</surname><given-names>M</given-names></name><name><surname>Zwicker</surname><given-names>C</given-names></name><name><surname>Schabussova</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>E. Coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization</article-title>. <source>Mucosal Immunol</source>. (<year>2019</year>) <volume>12</volume>:<page-range>132&#x02013;44</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41385-018-0084-6</pub-id>
</mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wells</surname><given-names>JM</given-names></name><name><surname>Mercenier</surname><given-names>A</given-names></name></person-group>. <article-title>Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria</article-title>. <source>Nat Rev Microbiol</source>. (<year>2008</year>) <volume>6</volume>:<page-range>349&#x02013;62</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nrmicro1840</pub-id>
</mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Medina</surname><given-names>E</given-names></name><name><surname>Guzman</surname><given-names>CA</given-names></name></person-group>. <article-title>Use of live bacterial vaccine vectors for antigen delivery: potential and limitations</article-title>. <source>Vaccine</source>. (<year>2001</year>) <volume>19</volume>:<page-range>1573&#x02013;80</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s0264-410x(00)00354-6</pub-id>
</mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grangette</surname><given-names>C</given-names></name><name><surname>Muller-Alouf</surname><given-names>H</given-names></name><name><surname>Goudercourt</surname><given-names>D</given-names></name><name><surname>Geoffroy</surname><given-names>MC</given-names></name><name><surname>Turneer</surname><given-names>M</given-names></name><name><surname>Mercenier</surname><given-names>A</given-names></name></person-group>. <article-title>Mucosal Immune Responses and Protection against Tetanus Toxin after Intranasal Immunization with Recombinant Lactobacillus Plantarum</article-title>. <source>Infect Immun</source>. (<year>2001</year>) <volume>69</volume>:<page-range>1547&#x02013;53</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/IAI.69.3.1547-1553.2001</pub-id>
</mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riese</surname><given-names>P</given-names></name><name><surname>Sakthivel</surname><given-names>P</given-names></name><name><surname>Trittel</surname><given-names>S</given-names></name><name><surname>Guzman</surname><given-names>CA</given-names></name></person-group>. <article-title>Intranasal formulations: promising strategy to deliver vaccines</article-title>. <source>Expert Opin Drug Delivery</source>. (<year>2014</year>) <volume>11</volume>:<page-range>1619&#x02013;34</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1517/17425247.2014.931936</pub-id>
</mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pandya</surname><given-names>T</given-names></name><name><surname>Joshi</surname><given-names>P</given-names></name><name><surname>Pathak</surname><given-names>R</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name></person-group>. <article-title>Nano-vaccination strategies: applications and challenges for intranasal immunization</article-title>. <source>Curr Pharm Biotechnol</source>. (<year>2023</year>) <volume>24</volume>:<page-range>946&#x02013;69</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2174/1389201023666220727105901</pub-id>
</mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mutsch</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Rhodes</surname><given-names>P</given-names></name><name><surname>Bopp</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>RT</given-names></name><name><surname>Linder</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Use of the inactivated intranasal influenza vaccine and the risk of Bell&#x02019;s palsy in Switzerland</article-title>. <source>N Engl J Med</source>. (<year>2004</year>) <volume>350</volume>:<fpage>896</fpage>&#x02013;<lpage>903</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa030595</pub-id>
<pub-id pub-id-type="pmid">14985487</pub-id>
</mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silva</surname><given-names>AL</given-names></name><name><surname>Soema</surname><given-names>PC</given-names></name><name><surname>Slutter</surname><given-names>B</given-names></name><name><surname>Ossendorp</surname><given-names>F</given-names></name><name><surname>Jiskoot</surname><given-names>W</given-names></name></person-group>. <article-title>Plga particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2016</year>) <volume>12</volume>:<page-range>1056&#x02013;69</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/21645515.2015.1117714</pub-id>
</mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Shu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name></person-group>. <article-title>Chitosan-based nanomaterial as immune adjuvant and delivery carrier for vaccines</article-title>. <source>Vaccines (Basel)</source>. (<year>2022</year>) <volume>10</volume>(<issue>11</issue>):<fpage>1906</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/vaccines10111906</pub-id>
<pub-id pub-id-type="pmid">36423002</pub-id>
</mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>KB</given-names></name><name><surname>Northeved</surname><given-names>H</given-names></name><name><surname>Kumar</surname><given-names>PE</given-names></name><name><surname>Permin</surname><given-names>A</given-names></name><name><surname>Gjetting</surname><given-names>T</given-names></name><name><surname>Andresen</surname><given-names>TL</given-names></name><etal/></person-group>. <article-title>
<italic>In vivo</italic> toxicity of cationic micelles and liposomes</article-title>. <source>Nanomedicine</source>. (<year>2015</year>) <volume>11</volume>:<page-range>467&#x02013;77</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.nano.2014.08.004</pub-id>
</mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Romoren</surname><given-names>K</given-names></name><name><surname>Fjeld</surname><given-names>XT</given-names></name><name><surname>Poleo</surname><given-names>AB</given-names></name><name><surname>Smistad</surname><given-names>G</given-names></name><name><surname>Thu</surname><given-names>BJ</given-names></name><name><surname>Evensen</surname><given-names>O</given-names></name></person-group>. <article-title>Transfection efficiency and cytotoxicity of cationic liposomes in primary cultures of rainbow trout (Oncorhynchus mykiss) gill cells</article-title>. <source>Biochim Biophys Acta</source>. (<year>2005</year>) <volume>1717</volume>:<page-range>50&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.bbamem.2005.09.011</pub-id>
</mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rizeq</surname><given-names>BR</given-names></name><name><surname>Younes</surname><given-names>NN</given-names></name><name><surname>Rasool</surname><given-names>K</given-names></name><name><surname>Nasrallah</surname><given-names>GK</given-names></name></person-group>. <article-title>Synthesis, bioapplications, and toxicity evaluation of chitosan-based nanoparticles</article-title>. <source>Int J Mol Sci</source>. (<year>2019</year>) <volume>20</volume>(<issue>22</issue>):<fpage>5776</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms20225776</pub-id>
<pub-id pub-id-type="pmid">31744157</pub-id>
</mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thakore</surname><given-names>S</given-names></name><name><surname>Valodkar</surname><given-names>M</given-names></name><name><surname>Soni</surname><given-names>JY</given-names></name><name><surname>Vyas</surname><given-names>K</given-names></name><name><surname>Jadeja</surname><given-names>RN</given-names></name><name><surname>Devkar</surname><given-names>RV</given-names></name><etal/></person-group>. <article-title>Synthesis and cytotoxicity evaluation of novel acylated starch nanoparticles</article-title>. <source>Bioorg Chem</source>. (<year>2013</year>) <volume>46</volume>:<fpage>26</fpage>&#x02013;<lpage>30</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.bioorg.2012.10.001</pub-id>
<pub-id pub-id-type="pmid">23247257</pub-id>
</mixed-citation></ref></ref-list><glossary><title>Glossary</title><def-list><def-item><term>APCs</term><def><p>antigen presenting cells</p></def></def-item><def-item><term>AuNPs</term><def><p>Gold nanoparticles</p></def></def-item><def-item><term>BALF</term><def><p>bronchoalveolar lavage fluid</p></def></def-item><def-item><term>Bm</term><def><p>Burkholderia mallei</p></def></def-item><def-item><term>BoHc</term><def><p>botulinum type A neurotoxin</p></def></def-item><def-item><term>BV</term><def><p>Bee venom</p></def></def-item><def-item><term>cCHP</term><def><p>Cationic-type CHP</p></def></def-item><def-item><term>Chi-C48/80</term><def><p>compound 48/80 loaded chitosan</p></def></def-item><def-item><term>Chi-PCL</term><def><p>Chitosan-poly epsilon caprolactone</p></def></def-item><def-item><term>CHP</term><def><p>cholesteryl group-bearing pullulan</p></def></def-item><def-item><term>CH/AL-BV</term><def><p>chitosan/alginate nanoparticle encapsulated bee venom</p></def></def-item><def-item><term>C-O-NP</term><def><p>curdlan-chitosan conjugate nanoparticle</p></def></def-item><def-item><term>CPC</term><def><p>Cetylpyridinium Chloride</p></def></def-item><def-item><term>CS</term><def><p>curdlan sulfate</p></def></def-item><def-item><term>CTA1-DD</term><def><p>cholera toxin A1 subunit -dimer of the D-fragment of protein A from Staphylococcus aureus bacteria</p></def></def-item><def-item><term>CT</term><def><p>cholera toxin</p></def></def-item><def-item><term>CTB</term><def><p>cholera toxin B subunit</p></def></def-item><def-item><term>DGNP</term><def><p>Dendritic Gold Nanoparticles</p></def></def-item><def-item><term>DOTAP</term><def><p>1,2-dioleoyl-3-trimethylammonium-propane</p></def></def-item><def-item><term>DT</term><def><p>diphtheria toxoid</p></def></def-item><def-item><term>ESs</term><def><p>expression systems</p></def></def-item><def-item><term>ESAT</term><def><p>Early Secretory Antigenic Target</p></def></def-item><def-item><term>GAS</term><def><p>Group A Streptococcus</p></def></def-item><def-item><term>GC</term><def><p>glycol chitosan</p></def></def-item><def-item><term>HA</term><def><p>hyaluronic acid</p></def></def-item><def-item><term>HAS</term><def><p>Human serum albumin</p></def></def-item><def-item><term>HBsAg</term><def><p>hepatitis B surface antigen</p></def></def-item><def-item><term>HBV</term><def><p>hepatitis B virus</p></def></def-item><def-item><term>HpaA</term><def><p>Helicobacter pylori adhesin A</p></def></def-item><def-item><term>HPV</term><def><p>human papillomavirus</p></def></def-item><def-item><term>IFN-I</term><def><p>type I interferons</p></def></def-item><def-item><term>IFN-&#x003b3;</term><def><p>interferon-gamma</p></def></def-item><def-item><term>IgA</term><def><p>immunoglobulin A</p></def></def-item><def-item><term>IgG</term><def><p>immunoglobulin G</p></def></def-item><def-item><term>IL-1</term><def><p>interleukin-1</p></def></def-item><def-item><term>IL-6</term><def><p>Interleukin-6</p></def></def-item><def-item><term>IVT DI</term><def><p>an RNA agonist of RIG-I</p></def></def-item><def-item><term>LNP</term><def><p>Lipid Nano Particle</p></def></def-item><def-item><term>LP</term><def><p>Lipopeptides</p></def></def-item><def-item><term>LPS</term><def><p>lipopolysaccharide</p></def></def-item><def-item><term>MA</term><def><p>mycolic acid</p></def></def-item><def-item><term>MA-Mc</term><def><p>MA-loaded micellar</p></def></def-item><def-item><term>MD</term><def><p>Maltodextrin</p></def></def-item><def-item><term>MdNP</term><def><p>Maltodextrin nanoparticles</p></def></def-item><def-item><term>Mtb</term><def><p>Mycobacterium tuberculosis</p></def></def-item><def-item><term>NALT</term><def><p>nasal-associated lymphoid tissue</p></def></def-item><def-item><term>NE</term><def><p>nanoemulsion</p></def></def-item><def-item><term>NF-&#x003ba;B</term><def><p>nuclear factor kappa-B</p></def></def-item><def-item><term>NPL</term><def><p>nanoparticles lipid</p></def></def-item><def-item><term>O-HTCC</term><def><p>O-(2-hydroxyl) propyl-3-trimethyl ammonium chitosan chloride</p></def></def-item><def-item><term>OVA</term><def><p>ovalbumin</p></def></def-item><def-item><term>PASP</term><def><p>pathogen-associated structural patterns</p></def></def-item><def-item><term>PEG</term><def><p>polyethylene glycol</p></def></def-item><def-item><term>PLGA</term><def><p>poly (lactic-co-glycolic acid)</p></def></def-item><def-item><term>PRRSV</term><def><p>porcine reproductive and respiratory syndrome virus</p></def></def-item><def-item><term>PspA</term><def><p>pneumococcal surface protein A</p></def></def-item><def-item><term>PVP</term><def><p>poly (4-vinylpyridine)</p></def></def-item><def-item><term>rPfCSP</term><def><p>recombinant P. falciparum circumsporozoite surface protein</p></def></def-item><def-item><term>SARS-CoV-2</term><def><p>Severe Acute Respiratory Syndrome Coronavirus 2</p></def></def-item><def-item><term>SMBVs</term><def><p>supramolecular biovectors</p></def></def-item><def-item><term>S-RBD</term><def><p>spike receptor binding domain</p></def></def-item><def-item><term>TE</term><def><p>total extract of Toxoplasma gondii antigens</p></def></def-item><def-item><term>Th1</term><def><p>type-1 helper T cell</p></def></def-item><def-item><term>Th2</term><def><p>type-2 helper T cell</p></def></def-item><def-item><term>Th17</term><def><p>type-17 helper T cell</p></def></def-item><def-item><term>TS-PDMS-grafted MP</term><def><p>3-(triethoxysilyl)-propyl-terminated polydimethylsiloxane-grafted microparticles</p></def></def-item><def-item><term>TTFC</term><def><p>C fragment of the tetanus toxin</p></def></def-item><def-item><term>VOCs</term><def><p>variants of concern</p></def></def-item></def-list></glossary></back></article>